1
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Abbreviated Title: Anti-BCMA-CAR T cells 
CC Protocol #: 14-C-0168
OSP#: 1404-1303
IBC#: RD-14-IV-06NCT#: [STUDY_ID_REMOVED]Version Date: September 21, 2017
Amendment: HTitle: A Phase I Clinical Trial of T Cells  Targeting B-Cell Maturation Ant igen for Previously 
Treated Multiple MyelomaPrincipal Investigator:                     [INVESTIGATOR_14407] N Kochenderfer, M.D.
A-F
                                                                                          Experimental Transplantation & Immunology Branch
Center for Cancer Research,National Cancer Institute, National Institutes of Health10 Center Drive, Rm. 3-3132, MSC 1203Telephone:  [PHONE_8683]
Email:  [EMAIL_9640]
Associate Investigators:  
Jennifer Mann, C.R.N.P., ETIB, CCR, NCI, NIHA-E Maryalice Stetler-Stevenson M.D., PhD., DTM, 
CCR , NCI, NIHE-F
Ronald Gress, M.D., ETIB, CCR, NCI, NIHA-FStephanie Cotton, R.N., OCD, CCR , NCI, NIHA-B
Steven Pavletic, M.D., ETIB, CCR , NCI, NIHA-FIrina Maric, M.D, CCR, NCI, NIHE-F
Brenna Hansen, R.N., OCD, CCR, NCI, NIHA-BDennis Hickstein, M.D., ETIB, CCR, NCI, NIHA-F
Jennifer Nicole Brudno,M.D., OCD, CCR, NCI, NIH 
A-F David Stroncek, M.D., DTM, CC, NIHE-F
Daniele Avila, C.R.N.P., ETIB, CCR, NCI, NIHA-ESeth Steinberg, Ph.D., OCD, CCR, NCI, NIHB, E
Fran Hakim, Ph.D, ETIB, CCR, NCI, NIHE-FConstance Yuan M.D., PhD., DTM, CC, NIHE-F
Bazetta Blacklock-Schuver, R.N., OCD, CCR, NCI, 
NIHA-B Thomas Hughes, Pharm.D., CC, NIHA-B
Steven Feldman M.D., SB, CCR, NCI, NIHA-FTracey Chinn, R.N, ETIB, CCR, NCI, NIHA-B
Referral Contact [INVESTIGATOR_52695]: Judith Lawrence, R.N.
[PHONE_10521], Fax: [PHONE_10522]
Email: [EMAIL_9641]
2
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Non-NIH Associate Investigator:
Judith Lawrence, R.N, Leidos Inc., A-B
For each person listed above, roles  are identifie d with the app ropriate letter
A.Obtain information by [CONTACT_505621] g or interacting with living in dividuals for research purposes
B.Obtaining identifiable private information about living individ uals
C.Obtaining the voluntary inform ed consent of individuals to be s ubjects
D.Makes decisions about subject eligibility
E.Studying, interpreting, or analyzi ng identifiable private information or data/sp ecimens for 
research purposes
F.Studying, interpreting, or analy zing de-identified data or spec imens for research purposes
G.Some/all research activities performed outside NIH
Investigational Agents: 
Drug Name: [CONTACT_74939]-BCMA-CAR-
transduced autologous
peripheral blood lymphocytes (PBL)
IND Number: [ZIP_CODE]
Sponsor: Center for Cancer Research
Commercial Agents: Cyclophosphamide, Fludarabine
3
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
PR√âCIS 
Background:
xMultiple myeloma (MM) is a malignancy of plasma cells. 
xMM is nearly always incurable.
xT cells can be genetically modified to express chimeric antigen  receptors (CARs) that 
specifically target malignancy-associated antigens.
xAutologous T cells genetically m odified to express CARs targeti ng the B-cell antigen CD19 
have caused complete remissions  in a small numbe r of patients w ith leukemia or lymphoma.  
These results demonstrate that C AR-expressing T cells have anti -malignancy activity in 
humans.
xB-cell maturation antigen (BCMA) is a protein expressed by [CONTACT_505622].
xBCMA is not expressed by [CONTACT_13541] c ells except for plasma cells a nd some mature B cells.
xWe have constructed an anti-BCMA CAR that can specifically reco gnize BCMA-expressing 
target cells in vitro and eradicat e BCMA-expressing tumors in m ice.
xAnti-BCMA-CAR-expressing T ce lls have not been previously teste d in humans.
xWe hypothesize that anti-BCMA-CAR-expressing T cells will speci fically eliminate BCMA-
expressing MM cells in patients
xPossible toxicities include cytokine-associated toxicities such  as fever, hypotension, and 
neurological toxicities.  Elimin ation of normal pl asma cells and unknown toxicities are also 
possible.
Objectives:
Primary
xDetermine the safety and feasibility of administering T cells exp ressing an anti-BCMA CAR 
to patients with MM.
SecondaryxEvaluate the in vivo persistence of anti-BCMA CAR T cells
xAssess for evidence of anti-myeloma activity by [CONTACT_14181]-BCMA CAR T cells
Eligibility:
xPatients must have meas urable MM defined as a serum M-protein ¬ï0.4 g/dL or a urine M-
protein¬ïPJKRXUVRUDQLQYROYHGVHUXPIUHHOLJKWFKDLQ)/&OH YHO ¬ïPJG/
(provided FLC ratio is abnormal) or a biopsy-proven plasmacytom a.
xPatients must have previously recei ved at least [ADDRESS_652280] a  normal creatinine a nd a normal cardiac eje ction fraction.
xAn ECOG performance status of 0 -2 is required.
4
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xPatients on any anticoa gulant medications except aspi[INVESTIGATOR_505566] t eligible.
xNo active infections are allowed.
x$EVROXWHQHXWURSKLOFRXQW¬ï P/SODWHOHWFRXQW¬ï 45,000/P/KHPRJORELQ¬ïJG/
x$/7DQG$67¬î 2.5-fold higher than the upper limit of normal
xAt least [ADDRESS_652281] emic treatment (including 
corticosteroids) and the r equired leukapheresis.
xAt least [ADDRESS_652282] elapse betw een the time of any prior systemic treatment (including 
corticosteroids) and initia tion of protocol treatment.
xBone marrow plasma cells must be 30% or less of total bone marro w cells 30 days or less 
prior to the start of protocol treatment.
xThe patient‚Äôs MM will need to be  assessed for BCMA expression b y flow cytometry or 
immunohistochemistry performed at the NIH.  If unstained, paraf fin-embedded bone marrow 
or plasmacytoma sections are ava ilable from prior biopsies, the se can be use d to determine 
BCMA expression by [CONTACT_505623]; otherwise patients will  need to come to the 
NIH for a bone marrow biopsy or other biopsy of a plasmacytoma to  determine BCMA 
expression.  The sample for BCMA e xpression can come from a bio psy obtained at any time 
before enrollment.
Design:
xThis is a phase I dose-escalation trial
xPatients will underg o leukapheresis
xT-cells obtained by [CONTACT_505624]-BCMA 
CAR
xPatients will receive a lymphocyt e-depleting chemotherapy condi tioning regimen with the 
intent of enhancing the activity  of the infused anti-BCMA-CAR-e xpressing T cells.
xThe chemotherapy conditioning  regimen is cyclophosphamide 300 m g/m2daily for 3 days 
and fludarabine 30 mg/m2daily for 3 days.  Fludarabine w ill be given on the same days a s 
the cyclophosphamide.
xTwo days after the chemotherapy ends, patients will receive an infusion of anti-BCMA-
CAR-expressing T cells.
xThe initial dose level of this  dose-escalation trial will be 0. 3x106CAR+ T cells/kg of 
recipi[INVESTIGATOR_419430].
xThe cell dose administered will be escalated until a maximum to lerated dose is determined
for patients in which less th an 50% of total bone marrow cells are plasma cells. With 
Amendment C, all patients with 50%  or greater bone marrow plasma  cells will receive 3x106
anti-BCMA CAR T cells/kg.
xFollowing the T-cell infusion, the re is a mandatory 9-day inpat ient hospi[INVESTIGATOR_505567].
5
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xOutpatient follow-up is pla nned for 2 weeks, and 1, 2, 3, 4, 6, 9, and 12 months after the 
CAR T-cell infusion.
xRepeat treatments are possible fo r patients with r esidual MM and no greater than grade 2 
toxicity with an initial treatment.
xRe-enrollment will be a llowed for a small number of subjects.
6
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652283] treatment ...................................... 11  
1.2.3  Allogeneic transplantation for MM .............................. .......................................... 12  
1.2.4  T-cell gene therapy ............................................ ..................................................... 13  
1.2.5  Chimeric antigen receptors ..................................................................................... 13  
1.2.6  BCMA..................................................................................................................... 15  
1.2.7  Anti-BCMA CAR development and preclinical testing ......................................... 18  
1.2.8  Rationale for immunosuppressive chemother apy and selection of l ymphocyte-
depleting chemotherapy regimen................................. ......................................................... 24  
1.2.9  Rationale for dose-escalation.................................. ................................................ 25  
1.2.10  Summary of risks and po tential benefits........................ ......................................... 26  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT.......................... ............................. 26  
2.1 Eligibility Criteria ........................................... ............................................................... 26  
2.1.1  Inclusion Criteria .................................................................................................... 26  
2.1.2  Exclusion criteria: ................................................................................................... 28  
2.2 Screening Evaluation........................................... ........................................................... 29  
2.3 Registration Procedures........................................ .......................................................... 30  
3 STUDY IMPLEMENTATION ........................................... ................................................. 30  
3.1 Study Design .................................................................................................................. 30  
3.1.1  General study plan ............................................. ..................................................... 30  
3.1.2  Protocol schema................................................ ...................................................... 32  
3.1.3  Dose Limiting Toxicity......................................... .................................................. 33  
3.1.4  Dose Escalation................................................ ....................................................... 33  
3.2 Dose Modifications/Delay....................................... ....................................................... 35  
7
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652284]-infusion outpatient evaluation............................ ............................................. 40  
3.5 Study Calendar ............................................................................................................... 43  
3.6 Gene-therapy-sp ecific follow-up................................ .................................................... 47  
3.7 Criteria for Removal from Protocol Therapy and Off Study Criter ia............................ 47  
3.7.1  Criteria for removal from protocol therapy ..................... ....................................... 47  
3.7.2  Off-Study Criteria ............................................. ...................................................... 48  
3.7.3  Off Protocol Therapy and Off-Study Procedure..................................................... 48  
4 CONCOMITANT MEDICATIONS/MEASURES............................... ............................... [ADDRESS_652285] support.......................................... .......................................................... 49  
4.3 Anti-emetics ...................................................................................................................4 9  
4.4 Granulocyte colony-stimulating factor.......................... ................................................. 49  
4.5 Avoidance of corticosteroids................................... ....................................................... 49  
4.6 Guidelines for management of common acute toxicities that occur  after CAR T cell 
infusions.................................................................................................................................... 50  
5 BIOSPECIMEN COLLECTION......................................... ................................................. 50  
5.1 CORRELATIVE STUDIES FOR RESEARCH............................... ............................. 50  
5.1.1  Biospecimen collection before the  start of the conditioning che motherapy:.......... 50  
5.1.2  Biospecimen collection after an ti-BCMA-CAR T-cell infusion during the required 
hospi[INVESTIGATOR_059]................................................ ....................................................................... 50  
5.1.3  Biospecimen collection durin g outpatient follow-up............. ................................. 51  
5.1.4  Immunological Testing .......................................... ................................................. 51  
5.1.5  Additional biopsies a nd additional blood draws................. .................................... 52  
8
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
5.1.6  Future studies................................................. ......................................................... 53  
5.2 Sample Storage, Tracking and Disposition.................................................................... 53  
5.2.1  Storage/Tracking in the Preclin ical Development and Clinical Mo nitoring Facility 
(PDCMF) ........................................................ ...................................................................... 53  
5.2.2  Protocol Completion/Sample Destruction ......................... ..................................... 54  
5.2.3  Samples for Genetic/Genomic Analysis ........................... ...................................... 54  
6 DATA COLLECTION AND EVALUATION..................................................................... 55  
6.1 Data Collection................................................ ............................................................... 55  
6.1.1  Adverse event recording: ....................................... ................................................. 56  
6.2 Genomic Data Sharing Plan ...................................... ..................................................... 56  
6.3 Response Criteria .............................................. ............................................................ 56  
6.3.1  Important Considerations on response criteria .................. ..................................... 56  
6.3.2  International Myeloma Workin g Group uniform response criteria: . ...................... 57  
6.4 Toxicity Criteria ............................................................................................................. 59  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN
60 
7.1 Definitions...................................................................................................................... 60  
7.1.1  Adverse Event.................................................. ....................................................... 60  
7.1.2  Suspected adverse reaction ..................................... ................................................ 60  
7.1.3  Unexpected adve rse reaction .................................... .............................................. 60  
7.1.4  Serious..................................................................................................................... 61  
7.1.5  Serious Adverse Event.......................................... .................................................. 61  
7.1.6  Disability..................................................... ............................................................ 61  
7.1.7  Life-threatening advers e drug experience....................... ........................................ 61  
7.1.8  Protocol Deviation (NIH Definition)............................ .......................................... 61  
7.1.9  Non-compliance (NIH Definition)................................ .......................................... 61  
7.1.10  Unanticipated Problem.......................................... .................................................. 61  
7.2 NCI-IRB and Clinical Director Reporting ........................ ............................................. 62  
7.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problem s and Deaths
62 
7.2.2  NCI-IRB Requirements for PI [INVESTIGATOR_10021] ..... ...................... 62  
7.2.3  NCI-IRB Reporting of IND Safety Reports........................ .................................... 62  
7.3 IND Sponsor Reporting Criteria .................................................................................... 63  
9
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
7.3.1  Reporting Pregnancy............................................................................................... 63  
7.4 Institutional Biosafety Committee (IBC) Reporting Criteria......................................... 64  
7.4.1  Serious Adverse Event Reports to IBC........................... ........................................ 64  
7.4.2  Annual Reports to IBC............................................................................................ 64  
7.5 Data and Safety Monitoring Plan................................ ................................................... 65  
7.5.1  Principal Investigator/Research Team ........................... ......................................... 65  
7.5.2  Sponsor Monitoring Plan ........................................ ................................................ 65  
7.5.3  Safety Monitoring Committee (SMC) .............................. ...................................... 66  
8 STATISTICAL CONSIDERATIONS.................................................................................. 66  
9 COLLABORATIVE AGREEMENTS ................................................................................. 68  
9.1 Cooperative Research and Development Agreement (CRADA)......... .......................... [ADDRESS_652286] Selection ................................................................................. 68  
10.2  Participation of Children ............................................................................................ 69  
10.3  Participation of Subjects Unable to Give Consent ............... ...................................... 69  
10.4  Evaluation of Benefits an d Risks/Discomforts................... ........................................ 69  
10.5  Consent and Assent Process and Documentation................... .................................... 70  
10.5.1  Telephone re-consent procedure ................................. ............................................ 70  
10.5.2  Short form consent process for  non-English speaking patients.............................. 70  
11 PHARMACEUTICAL INFORMATION..................................... ........................................ 71  
11.1  Retroviral Vector Containing  the anti-BCMA CAR Gene............ ............................. 71  
11.2  Cyclophosphamide ..................................................................................................... 71  
11.2.1  Source ......................................................... ............................................................ 71  
11.2.2  Toxicities................................................................................................................. 71  
11.2.3  Formulation and preparation.................................... ............................................... 72  
11.2.4  Stability and Storage............................................................................................... 72  
11.2.5  Administration procedures...................................... ................................................ 72  
11.3  FLUDARABINE.................................................... .................................................... 72  
11.3.1  Source ......................................................... ............................................................ 72  
11.3.2  Toxicity................................................................................................................... 73  
11.3.3  Formulation and preparation.................................... ............................................... 73  
11.3.4  Stability and Storage............................................................................................... 73  
10
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
12 Refere nces..................................................... ........................................................................ 74  
13 Appendices............................................................................................................................ 82  
13.1  Appendix A-Performance  Status Criteria......................... .......................................... 82  
13.2  APPENDIX B: Data Collection E lements Required By [CONTACT_1738]...... ........................ 83  
13.3  Appendix C:   Guidelines for man agement of common toxicities th at occur after CAR 
T-cell infusions ............................................... .......................................................................... 85  
13.4  Appendix D:   Infusion Instructions ............................ ............................................... 89  
11
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.1.1 Primary Objective
Determine the safety and feasibility of administering T cells e xpressing an anti-B-cell maturation 
antigen (BCMA) chimeric antigen receptor (CAR) to patients with  multiple myeloma (MM).
1.1.2 Secondary Objectives
xEvaluate the in vivo persisten ce and ex vivo function of T cell s expressing an anti-BCMA 
CAR.
xAssess infusions of anti-BCMA-CAR -expressing T ce lls for anti-MM activity.
1.2 BACKGROUND AND RATIONALE
1.2.1 IntroductionMultiple myeloma (MM) is a malignancy of plasma cells that is a lmost always incurable.  New 
therapi[INVESTIGATOR_419432].  Regressions of MM occurring in th e setting of allogeneic stem 
cell transplantation (alloHSCT), and particularly after allogen eic donor lymphocyte infusions 
(DLIs), provide evidence that cellular immune responses can hav e a clinically significant anti-
myeloma effect, but alloHSCT is associated with a significant t ransplant-related mortality and by 
[CONTACT_419535]-versus-host disease.
1,2Several patients have  obtained lengthy complete remissions 
of lymphoma or chronic lymphocytic  leukemia after infusions of autologous T cells that were 
genetically modified to express chimeric antigen receptors (CAR s) targeting the B-cell antigen 
CD19.3,4The lasting complete remissions of MM that sometimes occur in t he setting of 
alloHSCT and the encouraging early results obtained treating pa tients with anti-CD19-CAR-
expressing T cells provide a rationale for attempting to develo p CAR-T-cell therapi[INVESTIGATOR_419433].  
B-cell maturation antigen (BCMA) is a protein that is expressed  by [CONTACT_505625].5BCMA is also 
expressed by [CONTACT_505626] B cells, but BCMA is not expressed by 
[CONTACT_505627].5The very limited expression of BCMA in normal tissues makes BCM A a 
very promising target for CAR-T-cell therapi[INVESTIGATOR_014].  We have develo ped an anti-BCMA CAR, and 
we have demonstrated that T cells  expressing this CAR have BCMA -specific activity in vitro 
and in vivo.5Anti-BCMA-CAR-expressing T cells can eradicate MM tumors in mic e.5We 
propose to conduct a phase I clinical trial of anti-BCMA-CAR-ex pressing T cells.  This clinical 
trial will enroll patients with advanced MM that is progressive  despi[INVESTIGATOR_111776] [ADDRESS_652287] treatment
12
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Multiple myeloma (MM) is a neoplas m of monoclonal plasma cells.9,10For MM to be 
diagnosed, a patient must have a  proliferation of monoclonal pl asma cells plus other 
abnormalities such as an emia, renal insufficiency, hypercalcemi a, and lytic bone lesions.10MM
is the second most frequently occu rring hematologic cancer in t he [LOCATION_002] (U.S.).10An 
estimated 22,[ADDRESS_652288] MM 
comes from allogeneic transplantation studies.
1.2.3 Allogeneic transplantation for MM
Allogeneic stem cell transplant ation (alloHSCT) can cure a frac tion of patients with MM.19,[ADDRESS_652289] can induce long-term complete remissions  of MM, but also has a 
transplant-related mortality  rate (TRM) of 20% to 50%.19,20The high TRM of myeloablative
alloHSCT led investigators to t est nonmyeloablative alloHSCT fo r MM.19-21A commonly used 
transplantation strategy is to ad minister myeloablative chemotherapy plus an autologous stem 
cell transplant and then to conduc t a nonmyeloablative alloHSCT  a short time later.1,19,20in 
some studies, this strategy has  been shown to yield higher rates of progression-free and overall 
survival when compared to the s trategy of 2 sequential autologo us stem cell transplants.1,21One 
recent trial showed an 8-year progression-free survival rate of  22% for patients receiving an 
autologous transplant followed b y a nonablative alloHSCT compar ed to an 8-year progression-
free survival of 12% for patients receiving sequential autologous transplants.1These results 
1 3 
A b brevi ate d Title: A nti- B C M A- C A R T cells 
Versi o n D ate: Se pte m ber [ADDRESS_652290] e vi de n ce t hat l y m p h oc yt es ca n eli mi nate M M c o mes fr o m d o n or 
l y m p h oc yte i nf usi o ns ( D LIs). 2, 2 0 T we nt y-t w o t o t we nt y- ei g ht per ce n t of p atie nts recei vi n g D LIs 
t o treat persisti n g M M after all o H S C T ha ve ac hie ve d c o m plete re missi o ns ( C Rs). 2, 1 9, 2 0 Of n ote, 
s o me of t hese patie nt s o btai ni n g C Rs after D LIs di d n ot recei ve  a n y ot her t h era pi[INVESTIGATOR_77221] o u n d t he 
ti me of t heir D LI. 2T hes e res ults de m o nstrate t he a bilit y of t he i m m u ne s yste m t o e ra dicat e M M.  
U nf ort u natel y, b ot h all o H S C T a n d D LI s utilize all o ge nei c l y m p h o c yt es; t heref ore, t he y are 
ass ociate d wit h t he s o meti mes fa tal c o m plicati o n of graft- v ers u s- h ost disease 2, 1 9, 2 0 ; i n a d diti o n 
m ost patie nts recei vi n g D LIs f or M M d o n ot o bt ai n C Rs, s o de vel o pi n g of a n effecti ve 
a ut ol o g o us cell ular i m m u ne t hera p y f or M M w o ul d be a maj or a d v a nce. 
1. 2. 4 T-cell ge n e t hera p y 
T cells ca n b e pre p are d f or a d o p ti ve tra nsf er b y ge neticall y m o dif yi n g t h e T cells t o e x press 
rece pt ors t hat s pecificall y r ec o g nize t u m or-ass oci ate d a nti ge ns .2 2- 2 9 Ge netic m o dificati o n of T 
cells is a q uic k a n d r e lia ble pr ocess, a n d cli nical trials of g e neticall y m o difi e d T cells tar geti n g a 
variet y of mali g na n cies h a ve bee n carrie d o ut. 3, 4, 2 6, 3 0, 3 1 Ge neticall y m o difie d a nti ge n-s pecifi c T 
cells ca n be ge nerate d fr o m pe ri p heral bl o o d m o n o n uclear cells ( P B M C) i n s ufficie nt n u m bers 
f or cli nical treat me nt wit hi n [ADDRESS_652291] or y of safet y i n h u ma ns. 3 4- 3 6 T here ar e t w o ge neral a p pr oac h es f or ge n erati n g a nti ge n- 
s pecific T cells b y ge neti c m o di ficati o n:   i ntr o d uci n g ge n es e nc o di n g nat ur al T cell rece pt ors 
( T C Rs) or i ntr o d uci n g ge nes e nc o di n g c hi meric a nti ge n r ece pt ors  ( C A Rs). [ADDRESS_652292] C A Rs c urre ntl y u n der g oi n g c li nical a n d precli nical 
de vel o p me nt ar e a nti b o d y varia ble r e gi o ns. 2 3, 2 7, 3 7, 3 9 T C Rs rec o g nize pe pti des prese nte d b y 
h u ma n le u k oc yte a nti ge n ( H L A) m o lec ules; t heref ore, T C Rs are H L A-r estricte d, a n d a p artic ular 
T C R will o nl y be us ef ul i n patie nts e x pressi n g cert ai n H L A m ole c ules [ADDRESS_652293]  cell-s urface pr otei ns a n d gl yc o li pi [INVESTIGATOR_805], s o C A Rs are n ot H L A- 
restricte d, a n d C A Rs ca n be use d t o treat p atie nts re gar dl ess o f t heir H L A t y p es. 2 3, 2 6, 4 0- 4 2 
1. 2. 5 C hi meric a nti ge n rece pt ors 
Precli nical e x peri me nts e val uati n g C A R-e x pressi n g T cells as ca n cer t hera p y w ere i nitiate d i n 
1 9 9 3. 4 3, 4 4 T hese e x peri me nts le d t o a cli nical trial of C A R-tra ns d uce d T c ells tar geti n g t he -
f olate rece pt or o n o v aria n ca nce r cells; n o t u m or re gressi o ns w ere o bser ve d d uri n g t his cli nical 
trial. 4 5 C A Rs t hat were ca pa ble of rec o g niz i n g a v ariet y of t u m or- ass oci ate d a nti ge ns h a ve bee n 
14
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652294] been evaluated.3,46,55Different 
portions of CARs including antig en-recognition moieties, extrac ellular structural components, 
costimulatory domains such as th e cytoplasmic portion of the CD 28 protein, and T-cell-
activation moieties su ch as the signaling domains of the CD3 ]protein can all be important to the 
in vivo function of CAR-expressing  T cells, and all of these po rtions of CARs remain the subject 
of intensive investigation.37,46,50,56-58Much of the preclinical work e valuating CARs has been 
performed with CARs targeting the B-cell antigen CD19.7,46-48,53,59,60Data suggesting that T-cell 
costimulation played an important r ole in the activity of CAR-expressing T cells in vivo led 
investigators to add signaling mo ieties from the costimulatory molecule CD28 to CARs.48,57
These studies showed that adding  CD28 moieties to CARs enhanced antigen-specific cytokine 
production and proliferation b y anti-CD19 CAR T cells.57,61,62T cells expressing CARs with 
CD28 signaling moieties and CD3 ]signaling domains were more effective than T cells 
expressing CARs without CD28 moi eties at eradicating human leuk emia cells from mice.61,62
Subsequently, CARs incorporating  other signaling domains from c ostimulatory molecules such 
as 4-1BB (CD137) were developed.49Anti-CD19 CARs containing t he signaling domains of 
both 4-1BB and CD3 ]were superior to CARs containing the signaling domains of CD3 ]without 
any costimulatory domains at erad icating human malignant cells from mice.50,56Similar to 
CD28, including 4-1BB signaling moieties in CARs led to increas ed CD19-specific proliferation 
and enhanced in vivo persistence.50In contrast to T cells expre ssing a CAR with a CD28 
moiety, the increased in vitro proliferation and prolonged in v ivo persistence of T cells 
expressing a 4-1BB-containing C AR occurred whether or not the T cells were exposed to the 
antigen that the CAR recognized.50,[ADDRESS_652295] been reported to date in peer-
reviewed papers; these papers ha ve all reported results from pa tients receiving autologous CAR-
modified T cells.3,4,30,32,33,63,64The first evidence of antigen-s pecific activity of anti-CD19 CA R 
T cells in humans was generated du ring a clinical trial at the National Cancer Institute in a 
patient who experienced a drama tic regression of advanced folli cular lymphoma.32This clinical 
trial utilized a gamma retroviral vector to i ntroduce an anti-CD 19 CAR containing the signaling 
domains of the CD28 and CD3 ]molecules.32The anti-CD19 CAR-transduced T cells were 
prepared by [CONTACT_2329] a 24-day in v itro culture process.  The clini cal treatment reg imen consisted of 
lymphocyte-depleting chemothera py followed by [CONTACT_505628]-CD19 CAR T cells and a 
course of high-dose interleukin-2 (IL-2).  The first patient treated on this protocol had a large 
disease burden of follicular lym phoma.  This first patient expe rienced no acute toxicities except 
for a low grade fever that lasted for 2 days, and he obtained a  partial remission ( PR) that lasted 
for 32 weeks.32Bone marrow biopsies revealed a  complete elimination of extensi ve bone 
marrow lymphoma that was present before treatment; in addition,  normal B-lineage cells were 
completely eradicated from the bone marrow.32The bone marrow B-cell eradication was 
confirmed by [CONTACT_4133], a nd it persisted for over 36 weeks .32B cells were also completely 
absent from the blood during this time, while T c ells and other  blood cells recovered rapi[INVESTIGATOR_375].32
Seven months after the anti-CD 19 CAR T cell infusion, progressi ve lymphoma was detected in 
the patient‚Äôs cervical lymph nodes .  The lymphoma remained CD19+, so the patient was treated a 
15
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652296] etion, the depletion lasted for over 36 weeks. The B-cell depletion 
could not be attributed to the chemotherapy that was administer ed because blood B-cells 
recovered to normal levels i n 8 to 19 weeks in patients receivi ng the same chemotherapy plus 
infusions of T cells targeting N Y-ESO or gp100, which are antige ns that are not expressed by B 
cells.32Because normal B cells express C D19, prolonged normal B-cell depletion after anti-
CD19 CAR T-cell infusions demonstr ated that CAR-expressing T ce lls had a powerful ability to 
eradicate CD19+cells in humans.  All of the patient s with long-term B-cell dep letion obtained 
either complete or pa rtial remissions of the ir malignancies, an d the 4 patients with long-term B 
cell depletion also de veloped hypogammagl obulinemia.  Hypogamma globulinemia in these 
patients was routinely treated w ith infusions of intravenous im munoglobulins.  Of the eight 
patients treated, seven patients w ere evaluable for malignancy response; the one patient who was 
not evaluable died with pneum onia caused by [CONTACT_14302] A.4Six of the seven evaluable patients 
had remissions of their  malignancies.  Two of  the remissions we re complete remissions (CRs) of 
CLL.4Both of these CRs were confirmed by [CONTACT_505629] o f bone marrow cells.[ADDRESS_652297] patients 
treated with this regimen of che motherapy, anti-CD19 CAR T cell s, and IL-2 experienced 
significant acute toxicities in cluding fever, hypotension, and neurological toxicities such as 
delirium and obtundation.4All of these toxicities peake d within 10 days after the cell in fusion 
and resolved less than 3 week s after the cell infusion.4These acute toxicities correlated with
serum levels of the i nflammatory cytokines tumor necrosis facto r and interferon- J, and T cells 
producing these inflammatory cyt okines in a CD19-specific manner were detected in the blood 
of patients after the anti-CD19 CAR T cell infusions.4
1.2.6 BCMA
One candidate antigen for immunot herapi[INVESTIGATOR_505568] B-cell matur ation antigen (BCMA, 
CD269) 65,66.  BCMA RNA was detected univers ally in MM cells, and BCMA prot ein was 
detected on the surface of plasma  cells from multiple myeloma p atients by [CONTACT_223684] 
67-70.  BCMA is a member of the tumor  necrosis factor receptor (TNF)  superfamily 71,72.  BCMA 
binds B-cell activating factor (BAFF) and a pr oliferation induc ing ligand (APRIL) 72-74.  Among 
nonmalignant cells, BCMA has been  reported to be  expressed most ly by [CONTACT_505630] B cells 65,66,73,75,76.  Mice deficient in BCMA were h ealthy and had a normal physica l 
appearance 77,78.  BCMA-deficient mice had normal numbers of B cells, but survi val of long-
lived plasma cells was impaired 75,77.
A critical factor for any antigen being considered as a target for immunotherapi[INVESTIGATOR_505569]‚Äôs 
expression pattern in nor mal tissues.  BCMA has been reported to be expressed in plasma cells 
and in some B cells but to othe rwise have limited expression 65-67,76.  To more completely assess 
the expression pattern of BCMA, w e performed quantitative polym erase chain reaction (qPCR) 
on a panel of cDNA samples from a wide range of normal tissues (Figure 1).5As a positive 
control, we performed qPCR on c DNA from cells of a plasmacytoma that was resected from a 
16
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
patient with advanced MM.5Ninety-three percent of the cells  from the plasmacytoma sample 
were plasma cells as determined by [CONTACT_4133].  The BCMA ex pression of the 
plasmacytoma sample was dramatic ally higher than the BCMA expre ssion of any other tissue 
(Figure 1).  Not surprisingly, B CMA cDNA copi[INVESTIGATOR_505570] i n several hematologic tissues 
such as blood leukocytes, bone  marrow, spleen, lymph node, and tonsil.  Low levels of BCMA 
cDNA copi[INVESTIGATOR_505571].   In addition, low levels of 
BCMA cDNA copi[INVESTIGATOR_505570] i n most gastrointestinal organs such as duodenum, rectum, 
and stomach (Figure 1).  One possi ble explanation for BCMA expr ession in gastrointestinal 
organs and the trachea was the known presence of plasma cells a nd B cells in tissues such as 
lamina propria and Peyer‚Äôs Patches 79,80.
In Figure, 1 actin cDNA copi[INVESTIGATOR_014] a nd BCMA cDNA copi[INVESTIGATOR_505572], and the results were ex pressed as the number of BCMA c DNA copi[INVESTIGATOR_66487] 105actin 
cDNA copi[INVESTIGATOR_014].5

17
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
After demonstrating a very restr icted expression pattern of BCMA  RNA, we carried out an 
assessment of BCMA protein exp ression by [CONTACT_9064] ( IHC).  As expected, our 
anti-BCMA IHC staining procedure yielded strong staining of BCM A-K562 cells, which 
expressed high levels of BCMA af ter being transduced with the g ene encoding BCMA.  We 
found a lack of BCMA staining wit h NGFR-K562 negative control c ells.5We went on to 
evaluate BCMA protein expres sion in normal human organs.  Excep t for plasma cells, we did not 
detect BCMA protein expression b y the cells of any of the organ s that we stained.  We detected 
plasma cells expressing cell-su rface BCMA in gastrointestinal organs.  BCMA expression by 
[CONTACT_505631] B CMA expression by [CONTACT_505632].  
We detected BCMA-expressing pl asma cells in the tonsil.  The or gans assessed by [CONTACT_505633] t for plasma cells are shown  in Table 1.5We concluded 
that BCMA expression detected at low levels in some organs by [CONTACT_62865] (Figure 1) was due to 
plasma cells in these organs.
Table [ADDRESS_652298] be expressed on the surface of  MM cells. By [CONTACT_505634] 
18
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
patients with MM, we found that  6/10 tested samples uniformly e xpressed high levels of BCMA 
by [CONTACT_4133].  An example of  this flow cytometry staining is shown in Figure 2.
Figure 2
Events
BCMA
As shown in Figure 2, flow cytomet ry for BCMA (solid line) and i sotype-matched control 
staining (dashed line) revealed BCMA expression on the surface of MM cells from a 
plasmacytoma of a patient with MM.5The plot is gated on plasma c ells, which made up 93% of 
the total plasmacytoma cells.  In addition to the flow cytometr y studies, we stained tissue 
sections from plasmacytomas of  3 patients with MM.  In all 3 of  the samples, the neoplastic 
plasma cells expressed cell-surface BCMA.5
1.2.7 Anti-BCMA CAR developmen t and preclinical testing
Due to the expression pattern of BCMA, we reasoned that BCMA would be an appropriate target 
for CAR-expressing T cells.  To further assess the suitability of BCMA as a target for CAR-expressing T cells, we designed an anti-BCMA CAR.  The anti-BCMA CAR contained an scFv derived from one of two mouse an ti-human-BCMA monoclonal antibo dies 
81.   The anti-BCMA 
CAR also contained the hinge and transmembrane regions of the h uman CD8 Dmolecule, the 
signaling moiety of the CD28 cos timulatory molecule, and the si gnaling domains of the CD3 ]
molecule (Figure 3). 
Figure 3
CD28 CD8 hinge+TM CD3] Anti-BCMA scFv 3‚ÄôLTR 5‚ÄôLTR
We also designed a negative-control CAR named SP6.  The SP6 CAR  contained the variable 
regions of the hapten-speci fic SP6 monoclonal antibody 39.  Except for the different variable 
regions, the sequence of the SP6 CAR was identi cal to the seque nce of the anti-BCMA CAR.  
We ligated DNA encoding each of t he CARs that we designed into a gammaretroviral vector that 
has been used in previously in man y clinical trials of T-cell g ene therapi[INVESTIGATOR_014].4,24,26,32After 
transductions, we found high level s of cell surface expression of the anti-BCMA CAR on the 
transduced T cells (Figure 4).
Figure 4
19
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
CD8 CD8CAR+
CAR+Anti-BCMA CAR Untransduced
Figure 4 shows anti-BCMA CAR exp ression on T cells from Donor 1 6 days after transduction 
with gammaretroviruses encoding  the anti-BCMA CAR.  Transductio ns were carried out 2 days 
after the cultures were starte d, so the T cells had been in cul ture for a total of 8 days at the time 
of this analysis.  The plots are gated on live, CD3+lymphocytes.
We also performed a series of i n vitro assays to assess the fun ction of anti-BCMA-CAR-
expressing T cells, and we found that BCMA-CAR-expressing T cel ls exhibit BCMA-specific 
activities including CD107a upreg ulation and cytokine productio n in vitro.  These experiments 
showed that anti-BCMA-CAR-expre ssing T cells are activated in a  BCMA-specific manner.
20
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Figure5
BCMA-K562                        NGFR-K562Anti-BCMA CAR-transduced
Untransduced
BCMA-K562                       NGFR-K562CD107a
CD107aCD107aCD107aCD8 CD8
CD8 CD8
Figure 5 shows upregulation of CD 107a, which indicates degranulation and correlates with 
cytotoxicity82, when anti-BCMA CAR-expressing T  cells from Donor 1 were cultured with the 
BCMA-expressing cell line BCMA-K562.  CD107a was not upregulate d when anti-BCMA-
CAR-expressing T cells from Donor 1 were cultured for 4 hours w ith the BCMA-negative 
control cell line NGFR-K562.  Untransduced T cells from Donor 1  did not upregulate CD107a 
when cultured with either BCM A-K562 or NGFR-K562.  The plots ar e gated on live CD3+
lymphocytes.  The T cells depi[INVESTIGATOR_6517] 5 are from the sam e cultures as the cells shown in 
Figure 4 and were used in this ex periment on the same day of cu lture as the cells shown in 
Figure 4. 
T cells transduced with the anti- BCMA CAR produced large amount s of IFNJwhen they 
were cultured overnight with the B CMA-expressing cell lines BCM A-K562 and RPMI8226 
(Figure 6).  In contrast, the a nti-BCMA CARs produced only back ground levels of IFN Jwhen 
they were cultured with the BCMA-negative target cell lines NGF R-K562, CCRF-CEM, and 
A549.  The anti-BCMA-CAR-transduced T cells also made minimal I FNJwhen cultured without 
any target cell.  The experiment depi[INVESTIGATOR_6517] [ADDRESS_652299] IFN Jenzyme-linked immunosorbant assay (ELISA).
21
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Figure 6
Large fractions of anti-BCMA-CAR- transduced T cells produced th e cytokines IFN J, tumor 
necrosis factor (TNF), and interleukin-2 (IL-2) when cultured w ith the BCMA+target cell 
BCMA-K562 but not when cultured with the BCMA-negative cell lin e NGFR-K562 (Figure 7).  
For the assay described in Figure 7, T cells and target cells w ere cultured together for [ADDRESS_652300] the cytokines within the T 
cells as described previously.5The plots shown in Figure 7 are gated on CD3+lymphocytes.
22
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Figure 
7
CD4TNF
CD4IL-2
CD4
 CD4IFNJ
CD4TNF IL-2
CD4IFNJBCMA-K562                          NGFR-K562
BCMA-K562                        NGFR-K562
BCMA-K562                       NGFR-K562
Anti-BCMA-CAR-transduced T cells  also proliferated in a BCMA-spe cific manner.  
Figure 8 shows a carboxyfluorescein diacetate,succinimidyl ester ( CFSE) proliferation assay in 
which anti-BCMA-CAR-transduce d T cells were cultured for 4 days  with either BCMA-K562 
cells or BCMA-negative NGFR-K 562 cells.  CFSE was diluted to a g reater degree, indicating 
more proliferation, when the T cells were cultured with BCMA-K5 62 target cells (solid 
histogram in Figure 8) compare d to when anti-BCMA-CAR T cells w ere cultured with BCMA-
negative NGFR-K562 target cells .  The assay was conducted as de scribed previously.5
Figure 8
23
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Normalized event number
CFSE
We established RPMI8226 human mu ltiple myeloma cell line tumors  in immunodeficient mice.5
We allowed sizable tumors t o develop over 17 to 19 days then we treated the mice with a single 
intravenous infusion of anti-BCMA -CAR-transduced human T cells.   After infusion of anti-
BCMA-CAR T cells, dramatic regressions of all tumors occurred b etween day 6 and day 15 after 
the T cell infusion, and 100% of mi ce receiving anti-BCMA-CAR T  cells were cured (Figures 9 
and 10).5In contrast, tumors continued to i ncrease in size in all mice r eceiving infusions of T 
cells expressing a negative-cont rol CAR designated SP6.  The mi ce receiving infusions of anti-
BCMA-CAR-transduced T cells had no signs of toxicity during thi s experiment.
Figure 9
Anti-BCMA CAR
In the experiments depi[INVESTIGATOR_1230] i n Figures 9 and 10, anti-BCMA-CAR T cells were infused on Day 
0, and no other treatments were administered.  In the experiments reported in Figures 9 and 10, 
there were 10 mice in the anti- BCMA CAR and SP6 groups.  There were 7 mice in the untreated 
group.
Figure 10
24
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Myeloma cells from a plasmacytoma  of a patient with MM were spec ifically killed by 
[CONTACT_505635]-BCMA-CAR-trans duced T cells at low effector :target ratios while autologous T 
cells transduced with the negativ e control CAR SP6 caused only a low level of cytotoxicity  of 
the myeloma cells in a 4-hour cytotoxicity assay (Figure 11).5For all effector: a target ratio, the 
cytotoxicity was determined in dup licate, and the results are di splayed as the mean +/- the 
standard error of the mean.
Figure 11
1.2.8 Rationale for imm unosuppressive chemoth erapy and selection  of lymphocyte-depleting 
chemotherapy regimen
25
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
We plan to administer a conditioni ng chemotherapy regimen of cyclophosphamide and 
fludarabine before infusions of a nti-BCMA-expressing T cells be cause substantial evidence 
demonstrates an enhancement of the anti-malignancy activity of adoptively-transferred T cells 
when chemotherapy or radiother apy are administered before the T  cell infusions.6,8,83In mice, 
administering chemotherapy or radiotherapy prior to infusions o f tumor-antigen-specific T cells 
dramatically enhanced the anti-tu mor efficacy of the transferre d T cells.6,8,25,26,83,84
Administering chemotherapy or radiotherapy enhances adoptive T- cell therapy by [CONTACT_505636] T cells and elevat ion of T-cell stimulating serum 
cytokines including interleuki n-15 (IL-15) and interleukin-7 (I L-7), and possibly depletion of
myeloid suppressor cells and other mechanisms.6,8,84,85Removal of endogenous ‚Äúcytokine sinks‚Äù 
by [CONTACT_505637] T cells  and natural killer cells caused serum levels of important T-cell 
stimulating cytokines such as IL-[ADDRESS_652301] bee n shown to inhibit anti-tumor responses.85
Experiments with a syngeneic murine model sh owed that lymphocyt e-depleting total body 
irradiation (TBI) administered pr ior to infusions of anti-CD19- CAR-transduced T cells was 
required for the T ce lls to cure lymphoma.7In these experiments, some mice received TBI, and 
other mice did not receive TBI.  A ll mice were then challenged with lymphoma and treated with 
syngeneic anti-CD19-CAR T cells .  Mice receiving TBI had a 100% c ure rate and mice not 
receiving TBI had a 0% cure rate.[ADDRESS_652302] inclu ded cyclophosphamide and fludarab ine.3,4,31,32,87,88Both 
cyclophosphamide and fludarabine a re highly effective at deplet ing lymphocytes.87,88One well-
characterized and commonly use d regimen is the combination of 3 00 mg/m2of 
cyclophosphamide administered dail y for 3 days and fludarabine 30 mg/m2administered daily 
for three days on the same days as the cyclophosphamide.89Multiple cycles of this regimen can 
be tolerated by [CONTACT_505638].[ADDRESS_652303], t he anti-tumor efficacy of ado ptively-transferred T cell 
treatments increases as the dose  of T cells administered to mic e increases.90-92Second, in the 
setting of allogeneic transplanta tion, relapsed malignancy is o ften treated with infusions of 
allogeneic donor lymphocytes (DLIs).93,94The incidence of graft-versus-host disease, which is 
26
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652304] tissues , increases as the  dose of T cells 
administered in DLIs increases‚Äô.93,[ADDRESS_652305] benefit from participation in this trial.  Pati ents might also derive a benefit from 
knowing that they are contributin g to the development of new ce llular therapi[INVESTIGATOR_72911].  
Aiding in the development of new therapi[INVESTIGATOR_505573].
2ELIGIBILITY ASSESSMENT AND ENROLLMENT
2.1 ELIGIBILITY CRITERIA
Note: if a patient meets an elig ibility requirement as outlined below, and is enrolled on the 
protocol but then is found to no long er meet the eligibility req uirement after  enrollment but 
before the start of protocol treatment, the treatment will be a borted.
2.1.1 Inclusion Criteria
[IP_ADDRESS] Multiple Myeloma criteria
xClear BCMA expression must be det ected on greater than 50% of ma lignant plasma cells 
from either bone marrow or a plasmacytoma by [CONTACT_505639] 
27
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652306] be performed at the Na tional Institutes of 
Health. It is not required that the specimen used for BCMA deter mination comes from a 
sample that was obtained after the patient‚Äôs most recent treatm ent. BCMA expression 
will need to be documented on the majority of malignant plasma cells at some time after 
the original anti-BCMA CAR T- cell infusion in all patients unde rgoing a second anti-
BCMA CAR T-cell infusion.  If paraffin embedded unstained sampl es of bone marrow 
involved with MM or a plasmacytoma are available, these can be shipped to the NIH for 
BCMA staining, otherwise new biopsies will need to be performed  for determination of 
BCMA expression.
xBone marrow plasma cells must make up 30% or less of total bone  marrow cells based on 
a bone marrow biopsy performed within [ADDRESS_652307] one of the criteria below.
¬æOne or more of these abnormalit ies defines measurable disease:
¬æSerum M-protein greater or  equal to 0.4 g/dl (10 g/l). 
¬æUrine M-protein greater or equal to 200 mg/24 h.
¬æSerum free light chain (FLC) ass ay: involved FLC level greater or equal to10 mg/dl 
(100 mg/l) provided serum F LC ratio is abnormal.
¬æA biopsy-proven plasmacytoma
[IP_ADDRESS] Other inclusion criteria:
xGreater than or equal to [ADDRESS_652308] because of the 
potentially dangerous effects of the preparative chemotherapy o n the fetus.
xSeronegative for HIV antibody.  ( The experimental treatment bei ng evaluated in this 
protocol depends on an intact immune  system.  Patients who are HIV seropositive can 
have decreased immune -competence and thus are less responsive to the experimental 
treatment and more susceptib le to its toxicities.) 
xSeronegative for hepatitis B antigen, positive hepatitis B test s can be further evaluated by 
[CONTACT_505640], and if confirmatory tests are negative, the  patient can be enrolled.
28
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652309] be  tested for the presence of a ntigen by [CONTACT_937]-PCR and be 
HCV RNA negative.
xAbsolute neutrophil count greater than or equal to 1000/mm3without the support of 
filgrastim or other growth factors.  
xPlatelet count greater than or equal to 45,000/mm3without transfusion support 
xHemoglobin greater than 8.0 g/dl.  
xLess than 5% plasma cells in t he peripheral blood leukocytes 
xSerum ALT and AST less or e qual to 2.5 times the upper limit of  the institutional normal.
xSerum creatinine less than or equal to 1.3 mg/dL.
xTotal bilirubin less than or equal to 2.0 mg /dl, except in patie nts with Gilbert‚Äôs Syndrome 
who must have a total b ilirubin less than 3.0 mg/dl.
xAt least [ADDRESS_652310] elapse d since any prior systemic the rapy at the time the 
patient starts the cyclophospha mide and fludarabine conditionin g regimen, and patients‚Äô 
toxicities must have recovered t o a grade 1 or less (except for  toxicities such as alopecia 
or vitiligo). 
xBecause this protocol require s collection of autologous blood c ells by [CONTACT_505641]-BCMA-CAR T cells, systemic anti-myeloma t herapy including 
systemic corticosteroid steroi d therapy of greater than 5 mg/da y of prednisone or 
equivalent dose of another cor ticosteroid are not allowed withi n 2 weeks prior to the 
required leukapheresis.
xNormal cardiac ejection fractio n (greater than or equal to 50% b y echocardiography) and 
no evidence of hemodynamically sig nificant pericardial effusion as determined by [CONTACT_505642] 6 weeks of t he start of the treatment prot ocol.
xPatients should not take corticos teroids including prednisone, dexamethasone or any 
other corticosteroid for any  purpose at doses higher than 5 mg/d ay of prednisone or 
equivalent dose of another corticosteroid 2 weeks before apheres is and within 2 weeks 
prior to CAR T-cell infusion, a nd at any time after the CAR T c ell infusion.
2.1.2 Exclusion criteria: 
Patients on any anticoa gulants except aspi[INVESTIGATOR_419429].
xPatients that require urgent the rapy due to tumor mass effects or spi[INVESTIGATOR_13377].
xPatients that have active hemolytic anemia.
xPatients with second malignancies in add ition to multiple myelo ma are not eligible if the 
second malignancy has required t reatment within the past 3 year s or is not in complete 
remission. There are two excepti ons to this criterion: successfully treated non-metastatic 
basal cell or squamous c ell skin carcinoma.   
xWomen of child-bearing potential who are pregnant or breastfeed ing because of the 
potentially dangerous effects of t he preparative chemotherapy o n the fetus or infant.
29
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xActive systemic infections (defi ned as infections causing fever s or requiring anti-
microbial treatment), active co agulation disorders or other major uncontrolled medical 
illnesses of the cardiovascular, respi[INVESTIGATOR_696], endocrine, renal,  gastrointestinal, 
genitourinary or immune system, history of myocardial infarction , active cardiac 
arrhythmias, active obstructive or restrictive pulmonary diseas e.
xAny form of primary immunodeficiency  (such as Severe Combined I mmunodeficiency 
Disease). 
xSystemic corticostero id steroid therapy of greater than 5 mg/day of prednisone or 
equivalent dose of another cor ticosteroid are not allowed withi n 2 weeks prior to either 
the required leukapheresis or t he initiation of the conditionin g chemotherapy regimen.
xHistory of severe immediate hypersensitivity reaction to any of  the agents used in this 
study.
xHistory of allogeneic stem cell transplantation
xPatients with CNS metastases or s ymptomatic CNS involvement (in cluding cranial 
neuropathies or ma ss lesions and spi[INVESTIGATOR_13377]).
xPatients with active autoimmune s kin diseases such as psoriasis or other active 
autoimmune diseases such as rheumatoid arthritis.
2.[ADDRESS_652311] be completed within 30 days prior to starting the 
chemotherapy conditioning regime n unless otherwise noted (if not , then the evaluation 
must be repeated):
xComplete history and physical e xamination, including, weight an d vital signs, noting in 
detail the exact size and locati on of any lesions that exist. 
xConfirmation of diagnosis of MM by t he NCI Laboratory of Patholo gy and confirmation 
of clear BCMA expression on the m ajority of malignant plasma cel ls from either bone 
marrow or a plasmacytoma by [CONTACT_505643]. The sample 
used for this BCMA expression a nalysis can come from any time prior to enrollment on 
the protocol.
xBone marrow aspi[INVESTIGATOR_505574] .  Order cytogenetics with in terphase FISH and flow 
cytometry on the bone marrow aspi[INVESTIGATOR_337].  Cytogenetics studies are not required if a written 
report of cytogenetics studies  performed at any time are availa ble from an outside 
institution. The bone marrow biops y must take place at some time after the patient‚Äôs 
most recent myeloma treatment. If the patient agrees to future u se of specimens when 
screening bone marrow is obtai ned, reserve one tube of bone mar row aspi[INVESTIGATOR_505575]‚Äôs lab for researc h purposes.  Attention Jeremy Rose, Bldg 10, room 
12C216 contact [CONTACT_648]: [PHONE_10523]. (A bone marrow biopsy must al so be performed 
with in 30 days of starting the pr otocol treatment to assess for  disease burden. See section 
3.1.4 for details.)
30
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652312]. Stetler-Stevens on‚Äôs lab (NCI Laboratory of Path ology).
xEKG
xMRI of spi[INVESTIGATOR_203571] (only if clinically indicated in patien ts with back pain or pelvic 
pain or a history of plasmacytoma s of spi[INVESTIGATOR_505576]) 
xMRI of the brain-within 6 weeks  of protocol treatment start.
xIf necessary to document progressi ve disease obtain a skeletal X-ray survey
xDonor venous assessment
xAntibody screen for Hepatitis B and C; HIV, HTLV-I/II, T. cruzi  (Chagas agent), West 
Nile, and syphilis (RPR)
xCardiac echocardiograph-within 6 w eeks of protocol treatment start.
x(Sodium (Na), Potassi um (K), Chloride (Cl) , Total CO2 (bicarbon ate), Creatinine, 
Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium  total (Mg), 
Inorganic Phosphorus, Alkaline Phosphatase, ALT, AST, Total Bil irubin, Direct 
Bilirubin, LDH, Total Prote in, Total CK, Uric Acid)
xCBC with differential and platelet count
xSerum immunofixation electrophoresis
xSerum immunoglobulin free light chains
xGlucose-6-phosphate dehydrogenase (G6PD) deficiency screening
xThyroid panel 
xSerum Cortisol
x»ï-HCG pregnancy test (serum or  urine) on all women of child-bear ing potential 
2.[ADDRESS_652313] register an eligible candidate with NCI Ce ntral Registration Office (CRO) 
within [ADDRESS_652314] from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to:  NCI Central Registration Office  [EMAIL_978] .
After confirmation of eligibility at Central Registration Offic e, CRO staff will call pharmacy to 
advise them of the acceptan ce of the patient on the protocol pr ior to the release of any 
investigational agents.  Verif ication of Registration will be f orwarded electronically via e-mail to 
the research team. A recorder is available during non-working hours.
3STUDY IMPLEMENTATION
3.1 STUDY DESIGN
3.1.1 General study plan  
31
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652315] udy will undergo leukapheresis, and 
anti-BCMA-CAR-expressing T cells  will be generated by [CONTACT_505644]‚Äôs  T cells with a 
gammaretrovirus encoding the anti-BCMA CAR.  During the time of  T-cell preparation, the 
patients will receive a conditioni ng chemotherapy regimen of cy clophosphamide 300 mg/m2
daily for 3 days and fludarabine 30 mg/m2IV daily for 3 days on the same days.  This is an 
extensively-used chemotherapy regimen that can be easily adminis tered on an outpa tient basis.  
Two days after the end of the c onditioning chemotherapy, patien ts will receive a single infusion 
of anti-BCMA-CAR-expressing T cells.  A minimum 9-day hospi[INVESTIGATOR_505577]. Patie nts are required to stay within 60 
minutes driving time from the Clinical Center until day 14 afte r the CAR T-cell infusion.
Patients will then be e valuated for toxicit y and multiple myelo ma will be stage d 2 weeks and 1, 
2, 3, 4, 6, 9, and 12 months after the infusion.A small number of subjects may b e eligible for re-enrollment if  a patient is removed from the 
protocol BEFORE receiving any protocol therapy, and would be re quired to meet all eligibility 
criteria at the time of re-enrollment. Patients will be assigne d a new sequential study number for 
the re-enrollment study period. A ny cryopreserved cells produce d from a patient who was 
removed from the study can be use d to treat that patient after re-enrollment. We do not anticipate 
changes in the risk profile for t he initial versus re-enrollmen t.
32
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.1.2 Protocol schema
Leuka pheresis
In vitro generation of 
Anti-BCMA-expressing
T cells (9-11 days)Pretreatment staging
Infusion of recipi[INVESTIGATOR_505578]-BCMA-CAR-expressing T-Cells
(Inpatient for 9-days minimum post 
infusion )
Potential repeat treatments for patients with 
persistent myelomaFollow-up [ADDRESS_652316]-infusion.Outpatient or inpatient 
cyclophosphamide plus fludarabine 
conditioning chemotherapyPatient Baseline evaluation
33
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.1.3 Dose Limiting Toxicity
Dose-limiting toxicities are defined as follows:
oGrade 3 toxicities possibly or probably related to either the a nti-BCMA CAR T 
cells or the fludarabine and cyclophosphamide chemotherapy and l asting more 
than 7 days
oGrade 4 toxicities possibly or pr obably related to the study in terventions
The following specific toxicities will not be dose-limiting tox icities:
oNeutropenia (ANC<500/ PL) lasting 9 days or less
oAnemia (Hgb<8 g/dL) lasting [ADDRESS_652317] urbances regardless of grade
3.1.4 Dose EscalationThe trial will be a dose-escalation with 4 dose levels based on t he patient‚Äôs actual bodyweight.
As of amendment C, the number of anti-BCMA-CAR-expressing T cel ls transferred for each 
dose level will be as shown in the Dose Escalation Schedule bel ow. for patients in which less 
than 350% of total bone marrow cells are plasma cells. 
Dose Escalation Schedule
Dose Level Dose of IND Agent * 
Level 1 0.3x106CAR+ T cells per kg of recipi[INVESTIGATOR_505579] 2 1.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_419430] 
34
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Each dose level will include a minimum of 3 patients. There will  be a minimum of 9 days 
between the CAR T-cell infusion of a patient and the start of the co nditioning chemotherapy 
regimen for the next patient. Thi s will cause a 14 day delay betw een sequential CAR T-cell 
infusions.
Patients will be enrolled sequentially; therefore, enrollment w ill not proceed to a higher dose 
level until all patients have been treate d in the prior cohort.  If sufficient cells cannot be grown to 
meet the criteria for the assign ed dose level but sufficient cells can be grown to meet the 
requirements of one dose level lower than the assigned dose lev el, the patient w ill be enrolled in 
the appropriate dose level for th e number of cells infused. If a DLT occurs in an additional 
patient entered at a lower dos e due to cell growth limitations,  accrual will continue at this level 
as described in the dose-escalation scheme below.  Accrual will  be halted at the higher level until 
the cohort at the lower level i s complete as described below. If  sufficient cells cannot be 
produced to infuse the number of cells called for by [CONTACT_128243] l evel lower than the called for dose 
level, the treatme nt will be aborted.  A s econd attempt will be  made to prepare cells for the 
patient if the patient agrees and if the patient still meets al l eligibility criteria. 
Should none of the first  [ADDRESS_652318] 
patient.  Should 1 of 3 patients expe rience a dose limiting tox icity a particular  dose level,  three 
more patients would be treated a t that dose level to confirm th at no greater than 1/[ADDRESS_652319] 
a DLT prior to proceeding to the  next higher level.  If 1/[ADDRESS_652320] dose for a total of 6, in order to further 
characterize the safety of t he maximum tolerated dose.  
Starting with Amendment E, only patients with less than 30% bon e marrow plasma cells 
documented on a bone marrow biopsy w ill be enrolled. We have alre ady treated 4 patients on 
dose level 4 (9x106CAR+ T cells/kg).  One of 4 low- dose patients experienced a DLT on dose 
level 4.  If 2 more patients can be  treated on this dose level without a DLT, we will declare dose 
level 4 the maximum tolerate d dose and proceed to treat 8 patients on an expansion cohort as 
described on page 35 of t he protocol. If 2 mor e patients cannot be treated on Dose Level 4 
without a DLT, we will hold disc ussions with the FDA and NCI IR B to ask to proceed with a Level 3 3.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_505580] 4 9.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_419430]
35
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652321] achiev able dose level will be declare d the maximum feasible dose.
Dose escalation will follow the rules outlined in the Table bel ow.
Number of Patients with 
DLT
at a Given Dose LevelEscalation Decision Rule
0 out of 3 Enter up to 3 patients at the next dose level
>[ADDRESS_652322] opped.  This dose level will 
be declared the maximally administered dose 
(highest dose administered).  Up to three (3) additional patients will be entered at the next lowest 
dose level if only 3 patients were treated previously 
at that dose.
1 out of 3 Enter up to 3 more patie nts at this dose level.
xIf 0 of these 3 patients experience DLT, 
proceed to the next dose level.
xIf 1 or more of this group suffer DLT, then 
dose escalation is stopped, and this dose isdeclared the maximally administered dose.  UP to three (3) additi onal patients will be 
entered at the next low est dose level if only 3 
patients were treated p reviously at that dose.
<[ADDRESS_652323] be entered at 
the recommended phase 2 dose.
3.2 DOSE MODIFICATIONS /DELAY
Other Toxicity:
36
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652324] active infections defined as 
infections causing fevers or inf ections requiring anti-microbia l therapy that arise while 
patients are on-study but befor e the CAR T-cell infusion; howev er such patients are 
eligible for treatment if they meet all eligibility criteria af ter the infection resolves.  
oIf a patient experiences a grade  3 or greater toxicity (with th e exception of cytopenias 
including neutropenia, lymphopeni a, anemia, or thrombocytopenia) while on-study 
before the CAR T-cell infusion, t he CAR T-cell infusion must be  delayed until the 
toxicity improves to a grade 2 or less.
3.3 DRUG ADMINISTRATION
3.3.1 Leukapheresis
The patient will underg o a 10-15 liter leukaph eresis (generally , 12 liters will be processed to 
target a yield of 6-10 x109 lymphoc ytes) in the Department of T ransfusion Medicine (DTM) 
Dowling Apheresis Clinic accor ding to DTM standard operating pr ocedures.  The procedure 
requires dual venous access, and takes approximately 3-[ADDRESS_652325] operating procedures (SOPs).
Either freshly-collected cells  or cryopreserved cells can be us ed to initiate the cell-preparation 
process. Peripheral blood mononucl ear cells will be  isolated. Su fficient cells for 3 complete cell 
productions will be retained in t he Department of Transfusion M edicine; the excess cells will be 
sent to the ETIB Preclinical Cor e for cryopreservation at 100 to  200 million PBMC per vial.
Contacts in the ETIB preclinical  core are Fran Hakim and Jeremy  Rose ([PHONE_10524]). The 
anti-CD3 monoclonal antibody OKT3 will be used to stimulate T-cell proliferation. Two and 3
days after the start of the T- cell cultures, the cells will be transduced by [CONTACT_505645] a 
supernatant containing replica tion-incompetent gammaretroviruse s encoding the anti-BCMA 
CAR.  The cells will continue t o proliferate in culture until the day of infusion.  Anti-BCMA-
CAR T cells will be infused be tween day 8 and day 11 of culture . Ten vials of the infused cells 
will be cryopreserved and stored i n the ETIB preclinical core. E ach vial will contain 20 million 
cells.
Before infusion, the percentage of  T cells expressing the anti- BCMA CAR will be determined by 
[CONTACT_4133], and this percen tage of BCMA+ T cells will be us ed in calculating the total 
number of cells to be i nfused to meet the dose requirements of the dose-escalation plan described 
in 3.1.4.  In addition to flow cytometry, further testing of the  cells will take place prior to 
infusion to evaluate for microbi al contamination, replication-competent retroviruses, and 
viability.  Details of this tes ting can be found in the appropri ate DTM SOPs. When a patient is no 
longer eligible for retreatme nt on this protocol due to meeting  any of the off-study criteria listed 
in section 3.7.2, any remaining cryopreserved p retreatment PBMC collected on thi s protocol will 
be transferred from the Departme nt of Transfusion Medicine to t he Principle Investigator of this 
protocol for storage in the ETIB preclinical core and possible u se in research. 
37
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.3.3 Conditioning chemotherapy a nd anti-BCMA CAR T-cell administration-this can be 
either inpatient or outpatient
[IP_ADDRESS] Overall summary of  the treatment plan
Drug Dose Days
Cyclophosphamide 300 mg/m2IV infusion over 
30 minutes Daily x 3 doses on days -5,
-4, -3
Fludarabine 30 mg/m2IV infusion over 
30 minutes administered 
immediately following the cyclophosphamide on day -5, -4, -3Daily x 3 doses on days -5,
-4, -3
Anti-BCMA CAR T cells Variable. One time dose on day 0
[IP_ADDRESS] Detailed treatment plan
Retreatment decisions will be d ecided on a case-by-case basis t o include discussion with FDA.
Day -5, -4, and -3:  Patients will receive pre-hydration with 1 000 mL 0.9% sodium chloride I.V. 
over 1 to 3 hours. 
Patients will receive a nti-emetics following NIH Clinical Cente r guidelines, but dexamethasone 
will not be administered .  One suggested regimen is ondansetron 16 to 24 mg orally on d ays -5, 
-4, and -3 before chemotherapy (I.V. ondansetron can be substit u t e d ) .     P a t i e n t s  s hould be 
provided with anti-emetics such a s lorazepam and prochlorperazine to use at home.  
Next on days -5, -4, and -3, cyclophosphamide at a dose of 300 m g/m2I.V. will be diluted in 100 
ml 5% dextrose solution and infused over 30 minutes.  After the cyclophosphamide on days -5, -
4, and -3, patients will receive 30 mg/m2I.V. fludarabine in 100 mL 0.9% sodium chloride over 
30 minutes.  Note: in patients with a creatinine clearance of 30- 70 ml/minut e/1.73m2 , the 
daily dose of fludarabine will be reduced by 20%.
Following the fludarabine inf usion, patients will receive 1000 mL 0.9% sodium chloride I.V. 
over 1-2 hours. Furosemide w ill be given if needed.
Days -2 and -1:  No interventions except as needed for general supportive care such as anti-
emetics.  To minimize bladder to xicity, patients should increas e normal oral fluid intake to at 
least 2 L/day.Day 0:  Anti-BCMA CAR T cells will be administered.  Premedicati on for the cell infusion will 
be given approximately [ADDRESS_652326] identity label is 
double-checked by [CONTACT_74892] (MD or RN), and identifi cation of the product and 
38
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
documentation of administration ar e entered in the patient‚Äôs ch art as is done for blood banking 
protocols.  The cells are to be infused intravenously over [ADDRESS_652327] be infused over 20-30 minutes.  Details of the infusion pr ocedure are included in section 
13.3.
Days 1 to 9: Mandatory hospi[INVESTIGATOR_505581]. In addition, 
patients are required to stay within 60 minutes driving time fr om the Clinical Center until day 14 
after the CAR T-cell infusion.Guidelines for dealing with toxicities that often occur after C AR T cell infusions including 
hypotension, fever and tachycardia are given in Appendix 5.A CB C will be obtained daily.  If the 
absolute neutrophil count become s less than 500/microliter, fil grastim will be initiated at a dose 
of 300 micrograms daily subcutan eously for patients under 70 kg  in weight and at a dose of 480 
micrograms daily for patients over 70 kg in weight.  Filgrastim will be given daily and then
discontinued as soon as the abso lute neutrophil count recovers to 2000/microliter.
3.3.[ADDRESS_652328] undergo scree ning evaluation as listed in 
Section 2.2except infectious disease serol ogy, and brain MRI are not requi red to be repeated 
unless clinically indicated. In addition, serum will be screened for human anti-mouse antibodies
(HAMA) by [CONTACT_505646], and patients with HAMA 
reactivity that first appears after an initial anti-BCMA T-cell  infusion will not be  eligible for re-
treatment.  Follow-up testing for retreatment will be the same as for the first  treatment. The 
patient maybe re-enrolled on the t he study as a new patient to allow this re-tr eatment and these 
patients will be considerd in the t otal sample size for this study. A maximum of [ADDRESS_652329] be completed within 14 days of the star t of the conditioning 
chemotherapy regimen:
xPatients must have a central ve nous access before the time of c ell infusion.  This might 
require placement of a non-valv ed P.I.C.C line or other device.
39
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652330], abdom en, and pelvis or PET scan (only if necess ary for staging)
xSkeletal survey.  Additional s cans and x-rays may be performed if clinically indicated 
based on patients‚Äô signs and symptoms.
xIf necessary for staging: serum  immunofixation electrophoresis 
x250 microgram cosyntropin stimulati on test if suspi[INVESTIGATOR_505582] a  history  of adrenal 
insufficiency or other clinical indications
x24-hour urine collection with imm unofixation electrophoresis tim ed urine, and
creatinine for creatinine clearance calculation
xSerum immunoglobulin free light chains
xAnti CMV antibody titer, HSV ser ology, and EBV panel, T cruzi s erology, toxoplasmosis 
serology (Note: patients who a re known to be positive for any of the above do not need to 
be retested; may be performed w ithin 3 months of chemotherapy s tart date)
xSerum will be sent for measles IgG, Rubella IgG, VZV IgG, and p neumococcal 
antibodies (Ab) 23 serotypes
xBlood will be collected for resea rch purposes.  Draw 12 CPT tube s ([ADDRESS_652331]. Fran Hakim‚Äôs, Pre-Clinical Core lab; Attention Jeremy Ro se, Bldg 10, room 
12C216 contact [CONTACT_648]: [PHONE_10524].
xIn addition to the CPT tubes , draw 16 mL of blood to obtain ser um for research purposes 
([ADDRESS_652332] tubes, 8 mL per tube) within [ADDRESS_652333]. Fran Hakim‚Äôs, Pre-Clinical Core lab; Attention Jeremy Ro se, Bldg 10, room 
12C216 contact [CONTACT_648]: [PHONE_10524].
The following tests must be com pleted within 7 days of the start  of the conditioning 
chemotherapy regimen:
xTBNK 
xSodium (Na), Potassium (K), Chloride (Cl) , Total CO2 (bicarbonat e), Creatinine, 
Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium  total (Mg), 
Inorganic Phosphorus, Alkaline Phosphatase, ALT, AST, Total Bil irubin, Direct 
Bilirubin, LDH, Total Protein, T otal CK, Uric Acid (to be repeat ed on  the first day of the 
chemotherapy at the  discretion of the PI)
xE 2-microglobulin 
xSerum quantitative immunoglobulins
xABO typi[INVESTIGATOR_007]
40
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xIonized calcium
xCBC with differential and plat elet count(to be repeated on  the first day of the 
chemotherapy at the  discretion of the PI)
xPT/PTT
xUrinalysis; if results are a bnormal, send for urine culture
x»ï-HCG pregnancy test (serum or  urine) on all women of child-bear ing potential
3.4.2 Studies to be performed during the mandatory 9-day inpatient admission after cell 
infusion
xVital signs including pulse oximetry will be monitored q1h x 4 hours after completion of 
the CAR T cell infusion and every 4 hours otherwise unless othe rwise clinically 
indicated.
xDaily physical exam
xCBC twice a day from day 0 until day 10 with differential every 24 hours. After day 10 
do a CBC with differential daily until discharge.
xTBNK on the day of CAR T-cell in fusion (day 0) and day 7 after in fusion
xChemistries twice a  day starting from day 0 to day 10 .After day 10 do chemistries once a 
day until discharge: (Sodium (Na) , Potassium (K), Chloride (Cl),  Total CO2
(bicarbonate), Creatinine, Glucose, Urea nitrogen (BUN), Albumi n, Calcium total, 
Magnesium total (Mg), Inorganic Phosphorus, Alkaline Phosphatas e, ALT/GPT, 
AST/GOT, Total Bilirubin, Direct B ilirubin, LDH, Total Protein, Uric Acid )
xSerum C-reactive peptide (CRP ) within 7 days of day -5 before ini tiation of 
chemotherapy and daily while hospi[INVESTIGATOR_057].
xPT/PTT 7 days after cell infusion
xOther tests will be performe d, as clinically indicated.
xResearch blood:  Every Monday, Wednesday, and Friday during hosp italization, starting 
on the first Monday, Wednesday, or F riday after the day of CAR T-cell infusion and 
lasting up to 14 days after infusi on of anti-BCMA-CAR-transduced T cells, 56 mL of 
patient peripheral blood will be  obtained ([ADDRESS_652334] tube 8 mL).  
Attention Jeremy Rose, Bldg  10, room 12C216 contact [CONTACT_648]: 301-[ADDRESS_652335]-infusion outpatient evaluation
After completion of therapy the p atient will be f ollowed for po tential complications related to 
anti-BCMA‚ÄìCAR T-cell infusion. The  patient will be seen at the N IH in follow-up to evaluate 
disease status and lat e problems related to anti-BCMA ‚ÄìCAR T-cel l infusion at days +14, +30, 
+60, +90, and +120; and at 6, 9, and 12 months after anti-BCMA ‚Äì CAR T-cell infusion. After 
[ADDRESS_652336] the following tests performed to determine clinical respon se:
41
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
x6 CPT tubes of Research Blood (48 mL) will be collected to obtain blood for 
immunological testing. Attention Jeremy Rose, Bldg 10, room 12C216 contact [CONTACT_648]: [PHONE_10524].
x1 SST tube (8 mL) of Research B lood will be obtained for serum collection.  Attention 
Jeremy Rose, Bldg 10, room 12C216 contact [CONTACT_648]: [PHONE_10524].
Note: after the first year of follow-up, research blood will be reduce d to 4 CPT tubes 
(32 mL total) during re quired protocol visits .
xCT scan of chest, abdom en, and pelvis or PET scan at outpatient f ollow-up appointments 
starting 1 month after infusion ( only if a plasmacytoma was det ected before treatment)
xPhysical exam with vital signs and oxygen saturation
x(Sodium (Na), Potassium (K), Ch loride (Cl), Total CO2 (bicarbon ate), Creatinine, 
Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium  t o t a l  ( M g ) ,  
Inorganic Phosphorus, Alkaline P hosphatase, ALT, AST, Total Bil irubin, Direct 
Bilirubin, LDH, Total Prote in, Total CK, Uric Acid)
xE2-microglobulin
xTBNK
xBlood for serum quantitative immunoglobulins
xIonized calcium
xCBC with differential
xUrinalysis: if results are abnormal, send for urine culture
xSerum immunofixation electrophoresis 
x24-hour urine collection with immunofixation electrophoresis time d urine (can be 
omitted if not needed for staging af ter day 30. This is required f or all patients 
pretreatment and at the day 14 and day 30 follow-up appointments). Serum 
immunoglobulin free light chains
xAt the [ADDRESS_652337] be requested for  the flow cytometry.  BCMA immunohistochemistry should 
also be requested on the bone ma rrow biopsy. This may also be pe rformed at day +30 if 
clinically indicated.
xAt the day +180, day +270, and +1 year time points only, serum will be sent for measles 
IgG, Rubella IgG, VZV IgG, and pne umococcal antibodies (Ab) [ADDRESS_652338] be 
requested for the flo w cytometry.  BCMA immunohistochemistry sh ould also be 
requested on the bone marrow biopsy.
42
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xFor each bone marrow aspi[INVESTIGATOR_505583], send o ne tube of bone marrow aspi[INVESTIGATOR_505584]‚Äôs lab for research purpos es.  Attention Jeremy Rose, Bldg  10, room 12C316 
contact [CONTACT_648]: [PHONE_10523].
xGene-therapy-specific follow-up m ust be carried out as describe d in section 3.6
43
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.5 STUDY CALENDAR
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to [ADDRESS_652339], T. Bilirubin, D. Bilirubin, LDH, Total Protein, CK, Uric AcidXXXXXXXXXX X
Serum C-reactive peptide XhXmXm
PT/PTT XhX
Ionized calcium XhXXXXXXX X
Thyroid panel XK
44
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to 5 
years
E2-microglobulin  XhXXXXXXX X
Quantitative 
immunoglobulins XhXXXXXXX X
Anti-CMV, HSV, EBV, t.cruzi,toxoplasma  X
h,j
Antibody screen for 
Hepatitis B and C; HIV, HTLV-I/II, T. cruzi (Chagas agent), West Nile,
and syphilis (RPR)X
TBNK  XhXXXXXXXXX X
G6PD XK
Urinalysis (culture prn)  X XXXXXXX X
24 hr urine with 
immunofixation
electrophoresis timed urineX
hXXfXf Xf
XfXfXfXf
24 hr urine Creatinine ClearanceX
h
ABO typi[INVESTIGATOR_505585] X
45
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to [ADDRESS_652340]
c Xh
EKG, echocardiogram X
RCRXX   XX  Xg
Central Venous catheter placement  X
Donor Venous AssessmentX
Response Evaluation
Bone marrow aspi[INVESTIGATOR_337]/biopsy
d XXlXXe
46
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to 5 
years
Research Blood XX  XXXXXXX X
Adverse EventsX XXXXXXXX X
Concomitant Medications XX  XXXXXXXX X
Measles IgG, Rubella IgG, 
VZV IgG, Pneumococcal antibodies 23 serotypesX
hXXX
asee section 2.2and section 3.3.1 for details
bsee section 3.4.2 for details of testing during hospi[INVESTIGATOR_505586]<18 mg/dL or clinical suspi[INVESTIGATOR_505587], BCMA expression , cytogenetics, amyloid staining, and molecular studies of each  sample.
eonly if clinically indicated
fif useful for staging
gonly at 2, 3, 4, 5 year point, see section 3.6for details
honly at baseline
ionly D+30, no CTs or PETs indicated at D+14
jPatients who are known to be positive for any of these tests do  not need to be retested; may be performed within 3 months of c hemotherapy start 
date
konly at Screening
lonly Day  30 if clinically indicated
mDone Daily during hositalization
47
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652341] annually for long-term follow-
up of gene therapy .
xPersistence of CAR transduced c ells will be ass essed by [CONTACT_505647]/or flow 
cytometry at 1, 2, 3, 4, 6 and 12 months after cell infusion, or  until CAR-expressing cells 
are no longer detectable.  If an y patient shows a high level of  persistence of CAR gene 
transduced cells or an increasing population of CAR gene transd uced T cells at month 6 
or later (by [CONTACT_505648]), the previously archived sa mples will be subjected 
to techniques that would allow th e identification of predominant clonal populations of  
transduced cells.
xPatients‚Äô blood samples will be obt ained and undergo analysis fo r detection of replication 
competent retroviruses (RCR) by [CONTACT_419588] 3, 6, and [ADDRESS_652342] dose of s tudy therapy.
3.7.1 Criteria for removal from protocol therapy
Note that the treatment consists  of a conditioning chemotherapy  regimen followed by a T-cell 
infusion, so off-treatment criteri a mainly apply to eligibility  for potential repeat treatments and 
cancellation of cell infusion for t oxicity arising during the c onditioning chemotherapy. Patients 
will be taken off treatme nt for the following:
xGreater than grade 3 toxicity a ttributable to anti-BCMA CAR T cells makes patients
ineligible for repeat treatments.
xThe patient no longer meets the e ligibility criteria for the protocol after enrolling but 
before start of the chemotherap y conditioning regimen.  If the reason that the patient is 
not eligible can be rapi[INVESTIGATOR_505588] 2 weeks, the treatment can proceed if not, the 
patient will be off-study.
xThe patient receives any other treatment for multiple myeloma e xcept bisphosphonates 
and repeat treatment on this pr otocol.  Bisphosphonates are allowed when administered to 
prevent osteopenia more than 2 m onths after the anti-BCMA-CAR T-c ell infusion.  If a 
patient receives corticosteroid s in doses greater than 5 mg/day  of prednisone or an 
equivalent dose of another corticosteroid, the patient will be off-treatment.
48
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xGeneral or specific changes in  the patient‚Äôs c ondition render t he patient unacceptable for 
further treatment on this study in the judgment of the investig ator.
xParticipant requests to be w ithdrawn from active therapy
xInvestigator discretion
xPositive pregnancy test
3.7.2 Off-Study Criteria
Patients will be taken off study for the following:
x The patient voluntarily withdraws
x There is significant patient noncompliance
x Death
x PI [INVESTIGATOR_505589] 
x The patient no longer meets the e ligibility criteria for the pr otocol after enrolling but 
before start of the chemoth erapy conditioning regimen.
x Development of progressive or relapsed multiple myeloma after an ti-BCMA CAR T 
cell infusion in patients not desiring or not eligible for re-trea tment on this protocol.
x The patient receives any anti-m yeloma therapy except bisphospho nates.
Bisphosphonates are allowed 2 months  or more after the CAR T-ce ll infusion.
x Taking corticosteroids for any reason after CAR T-cell infusion i n a total cumulative 
dose of more than 30 mg of p rednisone or equivalent
Note: Patients must be followe d until all adverse events have r esolved to grade [ADDRESS_652343] notify Cent ral Registration Office (CRO) when a subject is taken off
protocol therapy and when a subj ect is taken off-study. A Participant Status Update Form from 
the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted e mail to:  NCI Central Registr ation Office  
[EMAIL_978].
4CONCOMITANT MEDICATIONS/MEASURES
4.1 ANTIBIOTIC PROPHYLAXIS
xPatients with a CD4 T-cell c ount less than 200 will be maintain ed on pneumocystis 
prophylaxis with trimethoprim-su lfamethoxazole 1 double-strengt h tablet every Monday-
49
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Wednesday-Friday. If patients cannot tolerate trimethoprim sulf amethoxazole, an 
alternative pneumocystis  prophylaxis will be used.
xPatients with serum IgG level  less than 400 mg/dL will receive intravenous 
immunoglobulin replacement as need ed to maintain an IgG level a bove 400 mg/dL, if the 
patient has serious bacterial infections.  An example of an int ravenous immunoglobulin 
infusion to be used for this pur pose would be Gammunex 500 mg/kg  given as a single 
dose.  Intravenous immunoglobuli n infusions should be preceded b y premedication with 
diphenhydramine and acetami nophen, and rate of infusion should be started at low rates 
and escalated in a step-wise manner.
xEmpi[INVESTIGATOR_505590] t on broad spectrum antibiotics w ith a first fever of 38.30C 
or greater or two fevers of 38.[ADDRESS_652344] 1 hour a nd concomitant ANC < 
500/ml. 
xAminoglycosides will be avoided unl ess clear evidence of sepsis .
4.[ADDRESS_652345] SUPPORT
xLeukocyte filters will be utiliz ed for all blood and platelet transfusions with the exception 
of the CAR-transduced T cell infusions to decrease sensitizatio n to transfused WBC and 
decrease the risk of CMV infection.
xPatients who are seronegative for CMV should receive CMV-negati ve blood products 
whenever possible.
xUsing daily CBC‚Äôs as a guide, the patient will receive platelet s and packed red blood cells 
(PRBC‚Äôs) as needed.  Attempts w ill be made to keep Hgb >8.0 gm/ dl, and platelets 
>10,000/mm3.  All blood products wit h the exception of the CAR- transduced T cells will 
be irradiated.  Leukocyte filte rs will be utilized for all PRBC  and platelet transfusions to 
decrease sensitization to trans fused WBC‚Äôs and decrease the ris k of CMV infection.
4.3 ANTI-EMETICS
Anti-emetics will follow NIH Clinical Center Guidelines (except that corticosteroids will be 
avoided).
4.4 GRANULOCYTE COLONY -STIMULATING FACTOR
A CBC will be obtained daily while  the patient is inpatient.  If  the absolute neutrophil count
becomes less than 500/microliter, Filgrastim will be initiated a t a dose of 300 mic rograms daily 
for patients under 70 kg in weigh t and a dose of 480 micrograms daily for patients over 70 kg in 
weight only in patients with absol ute neutrophil counts less th an 500/microliter.  F ilgrastim will 
be discontinued as soon as the absolute neutrophil count recove rs to 1500/microliter.
4.5 AVOIDANCE OF CORTICOSTEROIDS
Patients should not take corticos teroids including prednisone, dexamethasone or any other 
corticosteroid at a dose equiva lent to 5 mg/day or more of pred nisone for any purpose without 
approval of the Princ iple Investigator.
50
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652346] of blood d raws and acquisition of bone 
marrow aspi[INVESTIGATOR_505591].
5.1 CORRELATIVE STUDIES FOR RESEARCH
5.1.1 Biospecimen collection before  the start of the conditionin g chemotherapy:
xOne heparinized syringe containi ng 5 to 8 mL of bone marrow aspir ate to be sent to Fran 
Hakim‚Äôs lab.  Attention Jeremy Rose, Bldg 10, room 12C316 conta ct phone: [PHONE_10525].It will be used in functional assays to see if anti-BCMA-CAR T cells can recognize 
the patient‚Äôs multiple myeloma cells.
xBlood will be collected for res earch purposes.  A total of 12 CP T tubes ([ADDRESS_652347]. Fran Haki m‚Äôs, Pre-Clinical Core 
lab; Attention Jeremy Rose , Bldg 10, room 12C216 contact [CONTACT_648]:  [PHONE_10524].
x16 mL of blood will be drawn to obt ain serum for research purpos es ([ADDRESS_652348] tubes, 8 mL 
per tube) within [ADDRESS_652349]. Fran 
Hakim‚Äôs, Pre-Clinical Core lab; Attention Jeremy Rose, Bldg 10, room 12C216 contact [CONTACT_648]: [PHONE_10524].
xAn apheresis is required to obtai n cells used to prepare the an ti-BCMA CAR T cells that 
are administered on this protocol . After sufficient cells are p rocessed for all possible
clinical needs, the left over a pheresis cells can be cryopreser ved for research use. Note 
that these cells would simply be  discarded if not used for rese arch.
xSpecimens will be cryopreserved and assays will be performed re trospectively.
5.1.[ADDRESS_652350] Monday, 
Wednesday, or Friday after the CAR T-cell infusion and lasting u p until 14 days after infusion of 
anti-BCMA-CAR-transduced T cells , 56 mL of patient peripheral b lood will be obtained ([ADDRESS_652351] tube 8 mL). Attention Jeremy Rose, Bldg 10, room 12C216 contact [CONTACT_648]: [PHONE_10524].
51
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Additional research blood may be collected at any time during t he clinical course at the 
discretion of the PI (within the volume restriction limits) allow ing for the research studies 
already outlined in this protocol to be performed at the time of an unanticipated clinical event, if 
necessary to address the objectives of the study.
5.1.[ADDRESS_652352] year of follow up.
¬æ6 CPT tubes of Research Blood ( 48 mL) will be collected to obtain blood for 
immunological testing. Attention Jeremy Rose, Bldg 10, room 12C216 contact 
[CONTACT_648]: [PHONE_10524].
¬æ1 SST tube (8 mL) of Research B lood will be obtained for serum collection.  
Attention Jeremy Rose, Bldg 10, room 12C316 contact [CONTACT_648]: 301- 594-5339.
After 1 year research blood col lected will be reduced to 4 CPT tubes at each visit.
xAt the 2 month follow-up only, bone marrow aspi[INVESTIGATOR_505592].  
xOnly for patients with ongoing  responses, a second bone marrow aspi[INVESTIGATOR_505593] 6-month fo llow-up appointment , and the aspi [INVESTIGATOR_505594].
5.1.4 Immunological Testing
xT-cell assays: Direct immunologi cal monitoring will consist of quantifying CD3+ T cells 
that express the anti-BCMA CAR by [CONTACT_956], and/or by [CONTACT_4162] w cytometry.  These 
assays will be performed to measur e the persistence and estimat e the proliferation of the 
infused CAR+ T cells.  A quantitative PCR assay or a flow cytome try assay will be used 
to quantitate CAR+ T cells at a ll post-infusion time-points up to at least 3 to 6 months 
after infusion, and CAR+ T cell analysis will continue until the CAR+ T cell level drops 
to undetectable levels unless a stable low level of CAR+ T cell s is present at more than a 
year after infusion.  The absolute number of CAR+ PBMC will be estimated by 
[CONTACT_505649] R+ PBMC by [CONTACT_505650].  Ex vivo immunological assay s will be used to 
measure the BCMA-specific func tional activity of the CAR+ T cells and will consist of 
assays such as intracellular cy tokine staining and anti-CD107a degranulation assays. 
Immunological assays will be sta ndardized by [CONTACT_1116] p re-infusion recipi[INVESTIGATOR_505595] T cells cry opreserved at the time 
of infusion. 
xSerum cytokine levels will als o be measured by [CONTACT_28745]-linked im mune sorbent assays.   
52
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xGene expression studies will be performed on patient multiple m yeloma cells and on the 
infusion CAR T cells of each p atient.  Methods us ed will be eit her Nanostring and/or 
RNAseq (RNA sequencing).
xPatients‚Äô blood samples will be obt ained and undergo analysis f or detection of replication 
competent retroviruses (RCR) by [CONTACT_505651] [ADDRESS_652353] the Gibbon Ape Leukemia Virus (GALV) envelop gene and are 
performed under contract by [CONTACT_505652] m aintained by [CONTACT_505653].
xDue to nature of these studies, it is expected that expansion o f specific T-cell clones will 
be observed as T-cell proliferat e in response to the targeted a ntigen.  Therefore, care will 
be taken to track T-cell persistence, but presence of an oligoc lonal T cell population does 
not indicate an insertional mutagenesis event.  If any patient shows a high level of 
persistence of CAR gene trans duced cells or an increasing population of CAR gene 
transduced T cells at month 6 or l ater (by [CONTACT_419587]), the previously 
archived samples will be subject ed to techniques that would allow the identification of 
predominant clonal populations  of  transduced cells.  Such tech niques may include T cell 
cloning or LAM-PCR.  If a predo minant or monoclonal T cell clon e derived from CAR 
gene transduced cells is iden tified during the follow-up, the i ntegration site and sequence 
will be identified and subsequently analyzed against human geno me database to 
determine whether the sequences are associated with any known h uman cancers.  If a 
predominant integra tion site is observed, the T cell cloning or  LAM-PCR test will be 
used at an interval of no more t han three months after the first observation to see if the 
clone persists or is transient.  In all instances where monoclo nality is persistent and 
particularly in instances where  there is expansion of the clone , regardless of whether or 
not the sequence is known to be a ssociated with a known human ca ncer, the subject 
should be monitored closely for s igns of malignancy, so that tr eatment, if available, may 
be initiated early.
5.1.5 Additional biopsies and additional blood draws
Patients might be ask ed to undergo biopsies or additional blood  draws for research purposes. 
Additional blood draws might be necessary to investigate T cell  responses and serum cytokine 
levels in cases of clinical eve nts such as rapid regressions of  malignancy or t oxicity.  These 
research biopsies are optional and patients can p articipate in this trial whether or not they agree 
to undergo biopsies for researc h purposes.  These biopsies will only be performed if minimal 
morbidity is expected based on the  procedure performed and the granulocyte and platelet count.  
Biopsy tissue will be processed i n the NIH Department of Pathol ogy. Studies will be performed 
to evaluate the antigen expression by [CONTACT_505654]. 
In addition the pr esence of transduced cells ma y be quantitated.
53
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652354] may be banked and 
used in the future to investigat e new scientific questions rela ted to this study the patient provides 
consent for this. However, this research may only be done if the risks of the new questions were 
covered in the consent document. If new risks are associated wi th the research (e.g. analysis of 
germ line genetic mutations) a pr otocol amendment will be require d and informed consent will 
be obtained from all research s ubjects to whom these new studie s and risks pertain.
5.2 SAMPLE STORAGE ,TRACKING AND DISPOSITION
5.2.1 Storage/Tracking in the Pr eclinical Development and Clinic al Monitoring Facility 
(PDCMF)
xSamples will be ordere d in CRIS and tracked thr ough Clinical Trial Data Management 
system.  Should a CRIS screen not b e available,the CRIS downtim e procedures will be 
followed.  Samples will not be sen t outside NIH without IRB notification and an 
executed MTA. 
xPatient blood and tissue samples, c ollected for the purpose of research under IRB 
approved protocols of the Exper imental Transplantation and Immu nology Branch, may 
be archived by [CONTACT_505655] 
(PDCMF). All data associated wit h archived clinical research sam ples is entered into the 
ETIB PDCMF‚Äôs Microsoft Excel da tabases on frozen cells and serum . These databases 
are stored on the NCI group drive in the ETIB ‚ÄòPRECLINSERVICE‚Äô f older. Access to 
this folder is limited to PDCMF staff and ETIB clinical staff, re quiring individual login 
and password. All staff in the PDC MF laboratory receive annually  updated NIH/CIT 
training and maintain standa rds of computer security.
xThe data recorded for each sample  includes the patient ID, tria l name/protocol number, 
date drawn, treatment c ycle/post-transpla nt time point, cell so urce (e.g. peripheral blood, 
marrow,) as well as box and freez er location. Patient demograph ics that correlate 
treatment outcomes and therapi[INVESTIGATOR_505596]/ETIB clinical records. As of January 2007, all newly receiv ed samples receive a 
unique bar code number, which is included in the sample record i n the PDCMF database. 
Only this bar code is recorde d on the sample vial and the vials will not be traceable back 
to patients without authorized access to the  PDCMF database. All  non-coded samples 
previously archived will be str ipped of identifiers prior to distribution for any use other 
than as a primary objective of t he protocol under which they were collected.
xSamples are stored in freezers .  . All samples will be labeled solely with a bar code 
(which includes the date, and s erially determin ed individual sa mple identifier). The key 
will be available to a  restricted number of E TIB investigators and associate investigators 
on the protocol. Coded samples will be stored frozen at -20¬∞, -8 0¬∞ or liquid nitrogen 
vapor phase to -180 C acc ording to the stability requirements in a single location under 
the restricted control of the PDCM Facility of ETIB.
xAccess to samples from a protocol for research purposes will be  by [CONTACT_83939] [INVESTIGATOR_483434] (1) for research purposes 
associated with protocol objectives for which the samples were collected, or (2) for a new 
54
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
research activity following sub mission and IRB approval of a ne w protocol and consent, 
or (3) for use only as unlinke d or coded samples under the OHSR P Exemption Form 
guidelines stipulating that the activity is exempt from IRB rev iew. Unused samples must 
be returned to the PDCMF laboratory. Samples, and associated dat a, will be stored 
permanently unless the patient w ithdraws consent. If researcher s have samples remaining 
once they have completed all studies associated with the protoc ol, they must be returned 
to the PDCMF laboratory.
xThese freezers are located onsite at the Preclinical Service la boratory (12C216) (-85¬∞ 
freezer) or in ETIB common equipment space (CRC/3-3273).
5.2.2 Protocol Completion/Sample Destruction 
xOnce research objectives for the  protocol are achieved, researc hers can request access to 
remaining samples, providing t hey have both approval of the Pri ncipal Investigator of the 
original protocol under which the  samples or data were collecte d and either an IRB 
approved protocol and pa tient consent or an OHSRP exemption ind icating that the 
activity is exempt from IRB review.
xThe PDCMF staff will report to the Principal Investigators any d estroyed samples, if 
samples become unsalvageable because of environmental factors ( ex. broken freezer or 
lack of dry ice in a shippi[INVESTIGATOR_7788]), lost in transit betwe en facilities or misplaced by a 
researcher. 
xThe PI [INVESTIGATOR_505597] (ex. broken freeze r or lack of  dry ice in a shippi[INVESTIGATOR_34919]) or if a patient withdraws consent. Samples will also  be reported as lost if they 
are lost in transit between facilities or misplaced by a researcher.  Freezer problems, lost 
samples or other problems associ ated with samples will also be reported to the IRB, the 
NCI Clinical Director, an d the office of the CCR, NCI.
5.2.3 Samples for Genetic /Genomic Analysis
Samples will use for ge ne expression analysi s will be RNAseq and/ or NanostringTM.
These studies will be used to dete rmine gene expression in mult iple myeloma cells and 
infusion CAR T cells.  The purpose of these studies is to asses s gene expression at the 
RNA level not to study germline mutations.
[IP_ADDRESS] Description of the scope o f genetic/geno mic analysis
RNAseq and/or NanostringTMwill be used to determin e gene expression i n multiple myeloma 
cells and infusion CAR T cells.  T he purpose of these studies i s to assess gene expression at the 
RNA level not to study germline mu tations. One pur pose of these studies is to determine if 
different levels of gene expre ssion in malignant  cells are asso ciated with response to CAR T-cell 
therapy.  Another purpose of these  studies is to determine if d ifferent levels of  gene expression in 
infusion CAR T cells are associa ted with anti-malignancy respon ses caused by [CONTACT_81418] T cells or 
persistence of CAR T cells.
55
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
[IP_ADDRESS] Certificate of  Confidentiality 
As part of study efforts to provide confidentiality of subject information, this study has obtained 
a Certificate of Confidentiality, which helps to protect person ally identifiable research 
information. The Certificate of  Confidentiality allows investig ators on this trial to refuse to 
disclose identifying information related to the research partic ipants, should such disclosure have 
adverse consequences for subjects or damage their financial sta nding, employability, insurability 
or reputation. The informed cons ent includes the appropriate co verage and restrictions of the 
Certificate of Confidentiality.
[IP_ADDRESS] Management of ResultsThe analyses that we perform in our laboratory are for research purposes only; they are not 
nearly as sensitive as the tests that are performed in a labora tory that is certified to perform 
genetic testing. Changes that we observe unrelated to our resea rch may or may not be valid. 
Therefore, we do not plan to inform participants of the results  of testing on the tissue and blood 
that is performed in our research lab. However, subjects will b e contact[CONTACT_35114] a clinically 
actionable gene variant is disc overed. Clinically actionable fi ndings for the purpose of this study 
are defined as disorders appearing in the American College of M edical Genetics and Genomics 
recommendations for the return of incidental findings that is c urrent at the time of primary 
analysis. (A list of current guidelines is maintained on the CC R intranet: 
https://ccrod.cancer.gov/confluence/display/CCRCRO/Incidental+F indings+Lists) Subjects who 
still remain on the study will be  contact[CONTACT_148408] a  request to provide a blood sample to 
be sent to a CLIA certified laboratory. The CLIA testing may be  funded by [CONTACT_978] [INVESTIGATOR_505598]. If 
the research findings are veri fied in the CLIA certified lab, t he subject will be referred to the NCI 
Genetics Branch for genetic couns eling on the implications of t he results. Subjects that do not 
wish to return to the NCI will be referred to a local genetics health care provider (at their 
expense).This is the only time during the c ourse of the study that incidental findings will be returned. No 
interrogations regarding clinical ly actionable findings will be made after the primary analysis. 
Note: Subjects must remain on the study in order to maintain up  to date contact [CONTACT_505656]. Subject s opting for voluntary withdra wal from the study are to be 
informed at the time that results cannot be returned once this has been done.
6DATA COLLECTION AND EVALUATION 
6.1 D
ATA COLLECTION
Data will be prospectively collected and entered in real time i nto the Cancer Center Clinical Data 
System database (NCI C3D database) (information at http://ccrtrials.nci.nih.gov ). It is expected 
that clinical data be entered into C3D no later than after [ADDRESS_652355] will maintain complete records on each patie nt including any pertinent 
supplementary information obtaine d from outside laboratories, o utside hospi[INVESTIGATOR_600], radiology 
reports, laboratory reports, or o t h e r  p a t i e n t  r e c o r d s .  T h e  N C I  C3D will serve as the primary 
source from which all research  analyses will be performed.  
56
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652356] 
participant.
End of study procedures: Data will be stored according t o HHS , FDA regulations and NIH 
Intramural Records Retenti on Schedule as applicable. 
Loss or destruction of data: Should we become aware that a major breach in our plan to protec t 
subject confidentiality and trial  data has occurred, the IRB wi ll be notified. 
6.1.1 Adverse event recording:
xGrade 1 adverse events will not be recorded.
xGrade 2 adverse events that will be recorded:
a. Unexpected events that are possibly, probably, or definitely r elated to the 
research.
b. Expected events that are probably or definitely related to the  study interventions
will be recorded only for the first year after the infusion..
c. All Infections proven by [CONTACT_921] , PCR, antigen detection or ot her laboratory 
methods will be recorded for the f irst year after infusion regard less of attribution.
d. Any serious events that are deem ed clinically significant by [CONTACT_3433] e PI
[INVESTIGATOR_505599] 3, 4, and 5 adverse even ts will be recorded regardless  of attribution.
6.2 GENOMIC DATA SHARING PLAN
Unlinked genomic data w ill be deposited in the  database of geno types and phenotypes (dbGaP) 
in compliance with the NIH G enomic Data Sharing Policy.
6.3 RESPONSE CRITERIA
Responses will be categorized by [CONTACT_505657] m Response Criteria for Multiple 
myeloma.15Multiple myeloma staging will be conducted at the 2 week follow -up appointment 
and at each subsequent follow-up appointment.  T he appropriate staging studies will need to be 
determined for each patient becau se of the variability in multi ple myeloma.   
6.3.1 Important Considerations on response criteria
xResponse criteria for all categor ies and subcategories of respo nse except CR and sCR are 
applicable only to patients who ha ve ‚Äòmeasurable‚Äô disease by [CONTACT_505658] d to be stable in two evaluations made at any time.
[IP_ADDRESS] Definition of measurable disease
57
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Any one or combination of these  abnormalities defines measurabl e disease:
xBefore amendment E: Serum M-pro tein greater or equal to 1 g/dl (10 g/l). 
xAfter amendment E: S erum M-protein greater or equal to 0.4 g/dl ( 10 g/l). 
xUrine M-protein greater or equal to 200 mg/24 h.
xSerum FLC assay: involved FLC level greater or equal to10 mg/dl  (100 mg/l) provided 
serum FLC ratio is abnormal.
xPresence of a biopsy-proven plasmacytoma
[IP_ADDRESS] Laboratory tests for measurement of M-protein
xSerum M-protein level is quan titated using densitometry on SPEP  except in cases where 
the SPEP is felt to be  unreliable such as i n patients with IgA monoclonal proteins 
migrating in the beta region.  If  SPEP is not ava ilable or felt  to be unreliable (e.g., in 
some cases of IgA myeloma) fo r routine M-protein quantitation during therapy, then 
quantitative immunoglobulin levels on nephelometry or urbidomet ry can be accepted.  
However, this must be explicitl y reported, and only nephelometry can be used for that 
patient to assess res ponse and SPEP and nephe lometric values ca nnot be used 
interchangeably.
xUrine M-protein measurement is estimated using 24-h UPEP only.  (Random or 24 h 
urine tests measuring kappa and l ambda light chain levels are n ot reliable and are not 
recommended)
[IP_ADDRESS] Suggested follow-up t o meet response criteria 
xPatients with measurable diseas e by [CONTACT_505659] b e followed by [CONTACT_505660];
xExcept for assessment of sCR, CR, and VGPR, patients with ‚Äúmeas urable disease‚Äù 
restricted to the SPEP will n eed to be followed routinely only by [CONTACT_64827]; 
xPatients with ‚Äúmeasurable disease‚Äù restricted to the UPEP will need to be followed 
routinely only by [CONTACT_64828];
xPatients with ‚Äúmeasurable diseas e‚Äù in either SPEP or UPEP or bo th will be assessed for 
response only based on t hese two tests and not by [CONTACT_64829] ; 
xFLC response criteria are only applicable to patients without m easurable disease in the 
serum or urine, and to fulfill the requirements of the category  of sCR; 
xBone marrow is required only for categorization of CR 
xFor good clinical practice patie nts should be periodically scre ened for light chain escape 
with UPEP or serum FLC assay.
xPlasmacytomas can be staged with CT scans
6.3.2 International Myeloma Working Group uniform response crite ria: 
58
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
[IP_ADDRESS] Stringent Complete Remission (sCR)
xCR as defined below plus
oNormal FLC ratio and
oAbsence of clonal cells in bone m arrow by [CONTACT_505661] y (only1 bone marrow evaluation is needed).
[IP_ADDRESS] Complete Remission (CR) 
xNegative immunofixation on the serum and urine and
xDisappearance of any soft tissue plasmacytomas and
x5% or less plasma cells in bone m arrow (only 1 bone marrow evalu ation is needed)
xNo evidence of progre ssive or new bone lesi ons if radiographic studies were performed
(X-Rays not required in absence of clinical indication)
Comments: To be considered a CR, 
xBoth serum and urine immunofixation m ust be carried out and be negat ive regardless of 
the size of baseline M-protein in the serum or urine; 
xPatients with negative UPEP valu es pretreatment still require U PEP testing to confirm 
CR and exclude light cha in or Bence‚ÄìJones escape 
[IP_ADDRESS] Very Good Partial Remission (VGPR) 
xSerum and urine M-protein det ectable by [CONTACT_332864]
x90% or greater reduction in serum M-protein plus urine M-protein level <100mg per 24 h
xNo evidence of progre ssive or new bone lesi ons if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)
[IP_ADDRESS] Partial Remission (PR)
x50% or greater reduction of serum M-protein and
x90% or greater reduction in 24-h urinary M-protein (or to less than 200mg per 24 h) and
x50% or greater reduction in the s ize of soft tissue plasmacytom as, if present at baseline
xNo evidence of progre ssive or new bone lesions if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)
Only if the serum and urine M-protein are not measurable (as per  definition in section 
[IP_ADDRESS]),
x50% or greater decrease in the  difference between involved and uninvolved FLC levels 
is required (in lieu of the ser um and urine M-protein criteria) .
If serum and urine M-protein are  not measurable and serum FLC a ssay is also not 
measurable,  
59
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xBefore amendment E: 50% or great er reduction in plasma cells is  required in lieu of M-
protein evaluation (pr ovided baseline bone ma rrow plasma cell p ercentage was 30% or 
greater)
xAfter amendment E: bone marrow  plasma cell will not be used for  PR evalution.
[IP_ADDRESS] Stable Disease (SD) 
xNot meeting criteria for CR, VGPR, PR or prog ressive disease 
(Not recommended for use as an indicator of response; stability of disease is best described by 
[CONTACT_385921] t o progression estimates)
Comments:
xAll response categories require  two consecutive assessments mad e at any time before the 
institution of any new therapy; 
xConfirmation with repeat bone marrow biopsy not needed.
xPresence/absence of clonal FHOOVLVEDVHGXSRQWKH»õ »úUDWLR$QDEQRU PDO»õ»úUDWLRE\
immunohistochemistry and/or imm unofluorescence requires a minim um of 100 plasma cells 
IRUDQDO\VLV$QDEQRUPDOUDWL RUHIOHFWLQJSUHVHQFHRIDQDEQR UPDOFORQHLV»õ»úUDWLRQRI
greater than 4:1 or less than 1:2.
[IP_ADDRESS] Progressive Disease (PD)a
Requires one or more  of the following:
xIncreases of greater or equal  to 25% from the lowest post-treatm ent (nadir) value in
oSerum M-component (minimum ab solute increase of 0.5g/dl) or
oUrine  M-component (minimum ab solute increase of 200mg/24h) or
oPercentage of bone marrow plasma  cells (minimum absolute percen tage of 10%)
oSize of bone lesions or sof t tissue plasmacytoma
oOnly in patients without measurab le serum and urine M-protein l evels:  The 
difference between involved and uni nvolved FLC levels.  The abs olute increase must 
be >10 mg/dL.   The FLC ratio must be abnormal.
xDefinite development of new bone lesions or new plasmacytoma
xDevelopment of hypercalcemia sol ely attributable to the disease (corrected serum 
calcium >11.5 mg/dL)
aAll relapse categories require [ADDRESS_652357] udy.  The descriptions and grading scale s found in the revised NCI 
60
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Common Terminology Criteria for A dverse Events (CTCAE) version 4.[ADDRESS_652358] access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm#ctc_40 ). 
7SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN
7.[ADDRESS_652359] administrati on of investigational 
agent/intervention and have an attr ibution of at least possibly  related to the agent/intervention 
should be recorded and re ported as per sections 7.2,7.3and7.4.
An abnormal laboratory value will  be considered an AE if the la boratory abnormality is 
characterized by [CONTACT_39132]:
xResults in discontinuation from the study
xIs associated with clinical signs or symptoms 
xRequires treatment or any other  therapeutic intervention
xIs associated with death or anothe r serious adverse event, incl uding hospi[INVESTIGATOR_059]. 
xIs judged by [CONTACT_505662], the investigator will 
provide details about the  action taken with r espect to the test  drug and about the patient‚Äôs 
outcome.
7.1.2 Suspected adverse reactionSuspected adverse reaction means any adverse event for which th ere is a reasonable possibility 
that the drug caused the advers e event. For the purposes of IND  safety reporting, ‚Äòreasonable 
possibility‚Äô means there is evidence to suggest a causal relati onship between the drug and the 
adverse event. A suspected adve rse reaction implies a lesser de gree of certainty about causality 
than adverse reaction, which mean s any adverse event caused by a drug.
7.1.3 Unexpected adverse reaction
61
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
An adverse event or suspected adv erse reaction is considered ‚Äúunexpected‚Äù if it is not listed in 
the investigator brochure or i s not listed at the specificity o r severity that has been observed; or, 
if an investigator brochure is not required or available, is no t consistent with t he risk information 
described in the general investigational plan or elsewhere in the current application. 
"Unexpected‚Äù also refers to adve rse events or suspected adverse  reactions that are mentioned in 
the investigator brochure as occu rring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but are not specificall y mentioned as occurring with the 
particular drug und er investigation.
7.1.4 Serious 
An Unanticipated Problem or Proto col Deviation is serious if it me ets the definition of a Serious 
Adverse Event or if it compromises  the safety, welfare or rights  of subjects or others.
7.1.5 Serious Adverse EventAn adverse event or suspected adv erse reaction is considered se rious if in the view of the 
investigator or the sponsor, it results in any of the following :
xDeath,
xA life-threatening adverse drug experience
xInpatient hospi[INVESTIGATOR_505600]/birth defect.
xImportant medical events that m ay not result in death, be life- threatening, or require 
hospi[INVESTIGATOR_3767] a  serious adverse drug experi ence when, based upon
appropriate medical judgment, t hey may jeopardize the patient or subject and may require 
medical or surgical interventi on to prevent one of the outcomes listed in this definition.
7.1.6 Disability
A substantial disruption of a pe rson‚Äôs ability to conduct norma l life functions.
7.1.[ADDRESS_652360] caused death.
7.1.8 Protocol Deviation (NIH Definition)Any change, divergence, or departure from the IRB-approved research protocol.  7.1.9 Non-compliance (NIH Definition)The failure to comply with appli cable NIH Human Research Protec tions Program (HRPP)
policies, IRB require ments, or regulatory requirements for the protection of human research 
subjects.7.1.10 Unanticipated Problem
62
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Any incident, experie nce, or outcome that:
xIs unexpected in terms of nature , severity, or frequency in rel ation to 
(a) the research risks that ar e described in the IRB-approved r esearch protocol and 
informed consent document; Inves tigator‚Äôs Brochure or other stu dy documents, and
(b) the characteristics of t he subject population being studied ; AND
xIs related or possibly related t o participation in the research ; AND
xSuggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic , or social harm) than was prev iously known or 
recognized.
7.2 NCI-IRB AND CLINICAL DIRECTOR REPORTING
7.2.1 NCI-IRB and NCI CD Expedited Reporting of Unanticipated Pro blems and Deaths
The Protocol PI [INVESTIGATOR_52341]-IR B and NCI Clinical Director:
xAll deaths, except deaths  due to progressive disease
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
Reports must be received withi n 7 days of PI [INVESTIGATOR_10039] .
7.2.2 NCI-IRB Requirements for PI [INVESTIGATOR_118378]-IRB: 
1. A summary of all protocol devia tions in a tabular format to in clude the date the deviation 
occurred, a brief description of  the deviation and any correcti ve action.
2. A summary of any instances of non-compliance
3. A tabular summary of the following adverse events:
xAll Grade 2 unexpected events that are possibly, probabl y or definitely related to the 
research; 
xAll Grade 3 and 4 events that are  possibly, probably or definit ely related to the research; 
xAll Grade 5 events rega rdless of attribution; 
xAll Serious Events rega rdless of attribution. 
NOTE : Grade 1 events are not  required to be reported. 
7.2.3 NCI-IRB Reporting of IND Safety Reports
63
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652361] include an assessment of whether 
there is a reasonable possibility that the drug caused the event .
x All Grade 5 (fatal) events (ex cept death due to progressive disease) must be 
reported via email within [ADDRESS_652362] 
be reported withi n one business day
Study endpoints that are serious adverse events (e.g. all-cause  mortality) must be reported in 
accordance with the protocol unless there is evidence suggestin g a causal relationship between 
the drug and the event (e.g. deat h from anaphylaxis).  In that c ase, the investigator must 
immediately report the death to the sponsor.Events will be submitted to the Center for Cancer Research (CCR ) at: [EMAIL_1231]
and to the CCR PI [INVESTIGATOR_32528].7.3.1 Reporting Pregnancy
[IP_ADDRESS] Maternal exposure
If a patient becomes pregnant durin g the course of the study, t he study treatment should be 
discontinued immediately and the  pregnancy reported to the Spon sor. The potential risk of 
exposure of the fetus to the inve stigational agent(s) or chemot herapy agents (s) should be 
documented in box B5 of the MedWatc h form ‚ÄúDescribe Event or Pr oblem‚Äù.
Pregnancy itself is not regarde d as an SAE. However, as patients who become pregnant on study 
risk intrauterine exposure of t he fetus to agents which may be teratogenic, the CCR is requesting 
that pregnancy should be reporte d in an expedited manner as Gra de 3 ‚ÄúPregnancy, puerperium 
and perinatal conditions - Other (p regnancy)‚Äù under the Pregnanc y, puerperium and perinatal 
conditions SOC. Congenital abnormalities or birt h defects and spontaneous misca rriages should be reported and 
handled as SAEs. Elective abor tions without complications shoul d not be handled as AEs. The 
outcome of all pregnancies (spontan eous miscarriage, elective t ermination, ectopic pregnancy, 
normal birth, or congenital a bnormality) should be followed up and documented.
If any pregnancy occurs in the c ourse of the study, then the in vestigator should inform the 
Sponsor within [ADDRESS_652363] igator to ensure that all relevant 
information is provided to the S ponsor within 1 to 5 calendar days for SAEs and within 30 days 
for all other pregnancies.
64
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
The same timelines apply when outcome information is available.
[IP_ADDRESS] Paternal exposure
Male patients should refrain from fathering a child or donating  sperm during the study treatment, 
and for [ADDRESS_652364] cell infusion
Pregnancy of the patient‚Äôs part ner is not considered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarri age, elective termination, ectopic pregnancy, normal birth, or 
congenital abnormality) occurring from the date of the first do se until (120 days) after the last 
dose after last cell infusion s hould, if possible, be followed up  and documented.
7.4 INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) R EPORTING CRITERIA
7.4.1 Serious Adverse Event Reports to IBC
The Principal Investigator (or  delegate) will notify IBC of any u nexpected fatal or life-
threatening experience associated with the use of  anti-BCMA CAR  T cells as soon as possible 
but in no event later than [ADDRESS_652365] be reported t o the NIH IBC as soon as possible, 
but not later than 15 calendar days  after the investigator‚Äôsini tial receipt of the information.
Adverse events may be reporte d by [CONTACT_74910] 3500a.
7.4.2 Annual Reports to IBCWithin 60 days after the one-yea r anniversary of the date on wh ich the IBC approved the initial 
protocol, and after each subseque nt anniversary until the trial  is completed, the Principal 
Investigator (or delegate) sha ll submit the information describ ed below. Alternatively, the IRB 
continuing review report can be s ent to IBC in lieu of a separat e report.  Please include the IBC 
protocol number on the report.
[IP_ADDRESS] Clinical Trial Information
A brief summary of the status of  the trial in progress or complet ed during the previous year. The 
summary is required to include t he following information: 
xthe title and purpose of the trial
xclinical site
xthe Principal Investigator
[INVESTIGATOR_505601] (such as di sease indication and general 
age group, e.g., adult or pediatric); 
xthe total number of participan ts planned for i nclusion in the t rial; the number entered into 
the trial to date whose particip ation in the trial  was completed ; and the number who 
dropped out of the trial with a br ief description of the reason s
xthe status of the trial, e.g., open to accrual of subjects, clo sed but data collection ongoing, 
or fully completed, 
xif the trial has been complete d, a brief description of any stu dy results. 
65
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
[IP_ADDRESS] Progress Report and Data Analysis
Information obtained during the previous year's clinical and no n-clinical investigations, 
including: 
xa narrative or tabul ar summary showing the most frequent and mo st serious adverse 
experiences by [CONTACT_505663] e events submitted during the pa st year
xa summary of serious adverse eve nts that were expected or consi dered to have causes not 
associated with the use of the ge ne transfer product such as di sease progression or 
concurrent medications
xif any deaths have occurred, the  number of participants who died during participation in 
the investigation and causes of death
xa brief description of any inf ormation obtained that is pertine nt to an understanding of the 
gene transfer product‚Äôs actions , including, for example, inform ation about dose-response, 
information from controlled trials, and information about bioav ailability. 
7.5 DATA AND SAFETY MONITORING PLAN
7.5.1 Principal Investigator/Research Team 
The clinical research team wi ll meet on a regular biweekly basi s when patients are being actively 
treated on the trial to discuss each patient. Decisions about d ose level enrollment and dose 
escalation if applicable will be  made based on the toxicity dat a from prior patients. 
All data will be collected in a timely manner and reviewed by [CONTACT_458]. Adverse 
events will be reported as require d above. Any safety concerns,  new information that might 
affect either the ethical and or  scientific conduct of the tria l, or protocol dev iations will be 
immediately reported to the IRB  using iRIS and to the Sponsor. 
The principal investigator [INVESTIGATOR_505602]. The pr incipal investigator will perso nally conduct or supervise the 
investigation and provide appropr iate delegation of responsibili ties to other members of the 
research staff. 
7.5.2 Sponsor Monitoring Plan
As a sponsor for clinical trials, FDA regulations require the C CR to maintain a monitoring 
program. The CCR‚Äôs program allo ws for confirmation of: study da ta, specifically data that could 
affect the interpretation of pr imary study endpoints; adherence  to the protocol, regulations, and 
SOPs; and human subjects protec tion. This is done through indep endent verification of study 
data with source docume ntation focusing on:
xInformed consent process
xEligibility confirmation
xDrug administration and accountability
66
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652366]
7.5.3 Safety Monitoring Committee (SMC)This protocol will require oversig ht from the Safety Monitoring  Committee (SMC).  Initial 
review will occur as soon as possi ble after the annual NCI-IRB continuing review date.   
Subsequently, each protocol will  be reviewed as close to annual ly as the quarterly meeting 
schedule permits or more frequently as may be required by [CONTACT_941] S MC.   For initial and subsequent 
reviews, protocols will not be r eviewed if there is no accrual within the review period. Written 
outcome letters will be generate d in response to the monitoring activities and submitted to the 
Principal investigator [INVESTIGATOR_74837], CCR, NCI.
8STATISTICAL CONSIDERATIONS
The primary endpoint of this trial is to determine the safety o f administering anti-BCMA-CAR-
expressing T cells to patients with relapsed or persistent B-ce ll malignancies.  Secondary 
objectives of this trial are to measure any anti-malignancy eff ect that might occur, to assess the 
feasibility of administering anti-BCMA-CAR-expressing T cells, a nd to measure persistence and 
function of anti-BCMA-CAR -expressing T cells. 
The trial was to be a dose-escalation with 5 dose levels.  The n umber of anti-BCMA-CAR-
expressing T cells transferred f or each cohort was originally to  be as follows: 
Dose level 1 0.3x10
6CAR+ T cells per kg of recipi[INVESTIGATOR_505603] 2 1.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_505604] 3 3.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_505604] 4 9.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_505603] 5 15.0x106CAR+ T cells per kg of recipi[INVESTIGATOR_505605] E, we have completed accrual to the first 3 dos e levels using the approach 
described in the next 3 paragraphs. Each dose level will include  a minimum of 3 patients.  There 
will be a minimum of 7 days betw een the start of the conditioni ng chemotherapy regimen for 
sequential patients.  Patients will be enrolled sequentially; therefore, enrollment will not proceed 
to a higher dose level until all  patients have been treated in t he prior dose level.  If sufficient cells 
cannot be grown to meet the crite ria for the assigned cohort, t he patient will receive the dose of 
67
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652367] patient.  Should 1 
of 3 patients experience a dose limiting toxicity a particular dose level,  three more patients 
would be treated at that dose level to confirm that no greater than 1/[ADDRESS_652368] a DLT prior 
to proceeding to the next higher level.  If 1/[ADDRESS_652369] dose for a total of 6, 
in order to further characterize the safety of the maximum tole rated dose.  The maximum 
tolerated dose is the dose at which a maximum of 1 of 6 patient s has a DLT.  After a maximum 
tolerated dose is defined, additional patients can be treated o n this trial: up to [ADDRESS_652370] 9 re-
treated patients, or greater th an 1/[ADDRESS_652371] de cided to not enroll patients on do se level 5.  The plan for the 
future of this protocol is t o further explore dose level 4, 9.0 x106 CAR T cells/kg.  We have 
already treated 4 patie nts on dose level 4 (9x106CAR+ T cells/kg).  One o f 4 low-dose patients 
experienced a DLT on dose level  4.  If 2 more patients can be treated on this dose level without a 
DLT, we will declare dose leve l 4 the maximum tolerated dose and proceed to treat 8 patients on 
an expansion cohort as describ ed on page 35 of the protocol. If 2 more patients cannot be treated 
on Dose Level 4 without a DLT, w e will hold discussions with th e FDA and NCI IRB to ask to 
proceed with a lower dose to be de termined at that time.  Regarding the expansion cohort of 8 
patients, if more than 1 patient on this expansion cohort has a DLT, enrollment on the expansion cohort will stop.  We plan to tr eat a maximum of 10 more patients on this protocol (2 more on 
dose level 4 followed by [CONTACT_1629] e xpansion cohort of 8 patients).  W e have decided to not explore 
dose level 5.  As indicated in section 3.3.4, patients may be re-enrolled on the study as new 
patients to allow re-treatment, and these patient s will be cons idered both times in the total sample 
size for the study. With 18 patie nts enrolled as of January 5, 2 017, and an additional planned 
accrual of up to 10 patients, the t rial will enroll no more tha n 30 patients including up to 2
inevaluable patients.
68
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
The degree of persistence of anti-BCMA-CAR-transduced T cells w ill be evaluated by a 
quantitative measure (flow cytom etry or quantitative PCR) in all patients.  Anti-malignancy 
effects will be measured by [CONTACT_505664] a ccording to the International 
Uniform Response Criteria fo r Multiple Myeloma (Section 6.2). The clinical multiple myeloma 
responses will be interpreted cautiously in the context of a pi[INVESTIGATOR_505606] f uture protocols if warranted.
All other evaluations of secondary objectives will be performed using exploratory techniques. 
No formal adjustment for multiple comparisons will be used sinc e the evaluations are being done 
to generate hypotheses.
9COLLABORATIVE AGREEMENTS
9.1 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)
There is a CRADA for this protocol, with Bluebird Bio , Inc. for t he development of lentiviral 
based chimeric antigen receptors (CAR) vectors that target the B cell maturation antigen 
(BCMA) for the treatment of Multiple Myeloma.
CRADA #[ADDRESS_652372] 
always incurable disease; moreover, patients will have progress ive or relapsed myeloma 
despi[INVESTIGATOR_111776] [ADDRESS_652373] limited  life expectancies.  Subjects 
from both genders and all racial/ethnic groups are eligible for  this study if they meet the 
eligibility criteria.  To date, there is no information that su ggests that differences in 
disease response would be expected in one group compared to ano ther.  Efforts will be 
made to extend accrual to a representative population, but in t his preliminary study, a 
balance must be struck between patient safety considerations an d limitations on the 
number of individuals exposed to potentially toxic and/or ineff ective treatments on the 
one hand and the need to explore gender and ethnic aspects of c linical research on the 
other hand.  If differences in outcome that correlate to gender  or to ethnic identity are 
noted, accrual may be expanded or a follow-up study may be writ ten to investigate those 
differences more fully.
xMultiple myeloma (MM) remains an incurable disease despi[INVESTIGATOR_505607] t advances in
therapy.
xOver the last [ADDRESS_652374] recent era of im proved therapy with novel 
agents, the depth of the disease response to therapy (including  T- cells targeting B-cell 
maturation antigen) has remaine d the single most predictive fac tor for event free and 
overall survival in MM
xTherefore, improving the rate and depth of responses remains a high priority for clinical 
research in MM.
69
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xThis justifies the enrollment of all subjects with MM eligible f or T- cells targeting B-cell 
maturation antigen in this phase I /II study in an attempt to imp rove the clinical outcome 
while feasibility and safety are being evaluated.
xBecause patients on previous trial s  o f  C A R  T  c e l l s  h a v e  e x p e r i e nced hypotension, 
tachycardia, prolonged fevers, ne urological toxicities, and dep ressed myocardial function.  
In many cases these toxicities were severe enough to require in tensive care unit 
admission. We will limit enrollment to patients 70 years of age  or less because based on 
our admittedly limited experience with prior CAR-T cell clinica l trials, younger patients 
tolerate and recover from these toxicities better than elderly patients.
10.2 PARTICIPATION OF CHILDREN
Children will not be enrolled on this study.  Multiple myeloma is extremely uncommon in 
children; moreover, since the efficacy of this experimental procedure is unknown, it does not 
seem reasonable to expose child ren to this risk without further  evidence of benefit.  
10.[ADDRESS_652375] benefit from 
research participation (section 10.4DOOVXEMHFWV¬ïDJHZLOOEHRIIHUHGWKHRSSRUWXQLW\WRILO O
in their wishes for research and care, and assign a substitute decision maker on the ‚ÄúNIH 
Advance Directive for Health Care and Medical Research Participation‚Äù form so that another person can make decisions about their medical care in the event that they become incapacitated 
or cognitively impaired during the course of the study. Note: The PI [INVESTIGATOR_74840].  For those s ubjects that become 
incapacitated and do not have pre-determined substitute decisio n maker, the procedures 
described in MEC Policy 87-4 for appointing a surrogate decisio n maker for adult subjects who
are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of 
attorney, will be followed.
10.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS
The experimental treatment has a chance to provide clinical ben efit though this is unknown.  A 
goal of this study is to imp rove upon the number of patients who may benefit from adoptive cell 
therapy by [CONTACT_505665]-modi fied T-cells.  This specific p rotocol is being performed to 
evaluate a genetically modified T-cell therapy for multiple mye loma, which is a n almost always 
incurable disease.  Only patient s with multiple myeloma who hav e progressive or relapsed 
myeloma despi[INVESTIGATOR_111776] [ADDRESS_652376]  damage to normal tissues by [CONTACT_419530] T 
70
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652377] advanced multiple myeloma and limited life expectancies the potential benefit is 
thought to outweigh the potential risks.  It is also anticipate d that this study will provide 
scientific information relev ant to tumor immunotherapy.  
10.5 CONSENT AND ASSENT PROCESS AND DOCUMENTATION
The patient, along with family me mbers or friends, will be prese nted with a deta iled description 
of the protocol treatment.  The  specific requirements, objectives, and potential advantages and 
disadvantages will be presented.  T he Informed Consent document is given to the patient who is 
requested to review it and to as k questions prior to agreeing to participate in the treatment 
portion of this protocol.  The pa tient will be reassured that pa rticipation on trial is entirely 
voluntary and that he/she can withdraw or decide against treatm ent at any time without adverse 
consequences.The permission for additional biopsies for researc h will be obtained from patients 
at the time of the biopsy procedure. The research nurse, Princip al Investigator or his designee is 
responsible for obtaining writte n informed consent from the pat ient.
10.5.1 Telephone re-consent procedure
Reconsent on this study may be  obtained via telephone according to the following procedure: the 
informed consent document will be sent to the subject.  An explanation of the study will be 
provided over the telephone aft er the subject has had the oppor tunity to read the consent form.  
The subject will sign and date the informed consent. A witness to the subject‚Äôs signature [CONTACT_110730].  
The original informed consent  document will be sent back to the  consenting investigator who 
will sign and date the c onsent form with the  date the consent w as obtained via telephone.  
A fully executed copy will be r eturned via mail for the subject‚Äôs records.  The informed consent 
process will be documented on a pr ogress note by [CONTACT_505666] a copy of the 
informed consent document and note will be kept in the subject‚Äô s research record.
10.5.2 Short form consent process for non-English speaking patie nts
If there is an unexpected enrollme nt of a research participant for whom there is no translated 
extant IRB approved consent docum ent, the principal investigato r and/or those authorized to 
obtain informed consent will use th e Short Form Oral Consent Pr ocess as described in MAS 
71
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Policy M77-2, OHSRP SOP 12, 45 CFR 46.117 (b) (2) and 21 CFR 50.2 7 (b) (2).  The summary 
that will be used is the Englis h version of the extant IRB appr oved consent document. Signed 
copi[INVESTIGATOR_505608] w ill be filed in the 
medical record.
Unless the PI [INVESTIGATOR_505609]‚Äôs language, an interpreter will be present to 
facilitate the conversa tion. Preferably someone who is independ ent of the subject (i.e., not a 
family member) will assist in pr esenting information and obtaining consent. Whenever possible, 
interpreters will be pr ovided copi[INVESTIGATOR_505610] (24 to 48 hours if possible). 
We request prospective IRB appr oval of the use of the short for m process and will notify the IRB 
at the time of continuing review of the frequency of the use of the Short Form.
11PHARMACEUTICAL INFORMATION  
11.1 RETROVIRAL VECTOR CONTAINING THE ANTI -BCMA CAR G ENE 
The retroviral vector supernatant (PG13-MSGV-11D5-3CD828Z B1) e ncoding a chimeric 
antigen receptor (CAR) directed against B-cell maturation antig en (BCMA) was prepared and 
preserved following cGMP conditions in the Surgery Branch Vecto r Production Facility 
(SBVPF). The retroviral vector utilizes the MSGV retroviral vec tor backbone and consists of 
7007 bps including the 5' LTR from the murine stem cell virus ( promoter), packaging signal 
including the splicing donor (SD) and splicing acceptor sites,  t h e  a n t i - B C M A   C A R  p r o t e i n  
containing a signal peptide from human CD8-alpha, 11D5-3 light chain variable region (11D5-3
VL), linker peptide, 11D5-3 heavy chain variable region (11D5-3  VH), CD8 (hinge and 
transmembrane), CD28 (cytoplasmic region), and TCR zeta (cytopl asmic region), followed by 
[CONTACT_330430] 3'LTR. The physical titer was determ ined by [CONTACT_505667]. The supernatant will be store d at ‚Äì[ADDRESS_652378], supernatant will be delivered on 
dry ice to be used in in vitro transductions of T cells. There will be no re-use of the same u nit of 
supernatant for different patients. Retroviral titer has been s hown to be stable after immediate 
thawing and immediate use. Hand ling of the vector should follow  the guidelines of Biosafety 
Level-2 (BSL-2). The specific guidelines for Biosafety Level-2 (BSL-2) can be viewed at
http://bmbl.od.nih.gov/sect3bsl2.htm
11.2 CYCLOPHOSPHAMIDE
11.2.1 SourceCyclophosphamide will be purchased by [CONTACT_4517] P harmacy Department from 
commercial sources and is supp lied as a lyophilized powder in v arious vial sizes.
11.2.2 Toxicities
72
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
1) Nausea and vomiting - variable; symptomatically improved with standard anti-emetics 
and/or benzodiazepi[INVESTIGATOR_1651] [e.g., lorazepam].
2) Water retention ‚Äì cyclophosphamid e may rarely provoke the synd rome of inappropriate 
antidiuretic hormone secretion a nd resultant hyponatremia, usually manifested 12-48 hours 
after IV administration, necessitating frequent accurate assess ment [q 1-2 hours] of intake, 
urine output and urine specific gr avity. This effect can be cou nteracted by [CONTACT_22691]. 
Fluid restriction is not feasible during administration of high dose cyclophosphamide.
3) Cardiomyopathy - cyclophosphamid e may cause severe, sometimes lethal, hemorrhagic 
myocardial necrosis or congestive cardiomyopathy. Patients may present with congestive 
cardiomyopathy as late as [ADDRESS_652379] dose of cyclop hosphamide. The clinical 
syndrome has been observed in patients receiving the dose of cy clophosphamide used in 
this protocol. In an attempt to minimize this complication, pat ients with significant cardiac 
dysfunction are excluded from this protocol [see patient eligibi lity]. Congestive failure is 
managed according to standard medical therapeutics.
4) Hemorrhagic cystitis ‚Äì this is a serious, potentially life-thr eatening complication related to 
injury of the bladder epi[INVESTIGATOR_296911] m by [CONTACT_505668] s.
5) Although sub-clinical hematur ia is not uncommon at this dose level, clinically significant 
hematuria or serious hemorrhage can usually be avoided by [CONTACT_505669] a high urine 
volume and frequent voidings and the administration of Mesna. D iuresis is maintained for 
[ADDRESS_652380] rolytes is mandated. 
Furosemide may be required to ensure this diuresis. Continuous bladder irrigation may be 
used for control of significant hematuria.
6) Sterility
7) Less common but serious compli cations include pulmonary fibro sis and secondary 
malignancies. Less common but rev ersible toxicities include alo pecia and skin rash.
11.2.3 Formulation and preparation 
Reconstituted with sterile water for injection to yield a final  concentration of 20 mg/ml as 
described in the package insert.11.2.4 Stability and StorageVials are stored at room temperature. Following reconstitution as directed with sterile water for 
injection, cyclophosphamide is s table for 24 hours at room temp erature or 6 days when kept at 2-
8¬∞C.  Once diluted for administration, cyclophosphamide will be  provided an expi[INVESTIGATOR_505611].
11.2.5 Administration proceduresThe cyclophosphamide used in this regimen will be given as Intr avenous infusion over 30
minutes. 11.3 FLUDARABINE
11.3.1 Source Fludarabine monophosphate will be purchased by [CONTACT_505670] a white, lyophilized  powder. Each vial contains 50 
73
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652381] pH.  
Fludarabine is stored a t room temperature.
11.3.2 Toxicity 
Fludarabine toxicities include m yelosuppression (dose limiting toxicity), fever, nausea, vomiting, 
stomatitis, diarrhea, gastrointestinal bleeding, anorexia, edem a, skin rashes, myalgia, headache, 
agitation, hearing loss, transient epi[INVESTIGATOR_505612] f atigue, auto-immune hemolytic 
anemia, auto-immune thrombocytope nia, paresthesias, peripheral neuropathy, renal, and 
pulmonary toxicity (interstitial pneumonitis). Severe fatal CNS  toxicity presenting with loss of 
vision and progressive deteriora tion of mental status were enco untered almost exclusively after 
very high doses of fludarabine monophosphate. Such toxicity has  only rarely been demonstrated 
at the 25-30 mg/m2/day dosage of f ludarabine. Very rarely descr ibed complications include 
transfusion-associated graft-ver sus-host disease, thrombotic th rombocytopenic purpura, and liver 
failure. Tumor lysis syndrome following fludarabine administration has been observed, 
especially in patients with advanced bulky disease. Opportunist ic infections (protozoan, viral, 
fungal, and bacterial) have been observed post-fludarabine, esp ecially in heavily pre-treated 
individuals, and in individuals rec eiving fludarabine combined with other agent.
11.3.[ADDRESS_652382] the pH to 7‚Äì8.5. Fludarabine will be dilute d in 100 to 125ml of either 5% 
dextrose in water or 0.9% sodium c hloride, and infused IV over [ADDRESS_652383] be taken 
to assure the sterility of the prepared solution. Once diluted f or administration, f ludarbine will be 
provided an expi[INVESTIGATOR_505613] N IH CC Pharmacy 
DepartmentAdministration proceduresParenteral drug products should be inspected visually for parti culate matter a nd discoloration 
prior to administration. Fludara bine is administered as an IV in fusion in 100 ml 0.9% sodium 
chloride, USP over 15 to 30 minutes.  Dose reduction for renal impairment
For Creatinine Clearance of 30- 70 mL/min/1.73m2 there will be a 20% dose reduction. If the 
Creatinine Clearance is less th an 30mL/min/1.73m2, Fludarabine will not be administered.  
74
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
12 REFERENCES
1. Gahrton G, Iacobelli S, Bj√∂rkstrand B, et al. Autologous/reduce d-intensity allogeneic 
stem cell transplantation vs a utologous transplantation in mult iple myeloma: long-term 
results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055-5063.
2. Salama M, Nevill T, Marcellus D , et al. Donor leukocyte infusion s for multiple myeloma. 
Bone Marrow Transplantation. 2000;26(11):1179-1184.
3. Kalos M, Levine BL, Porter DL, e t al. T cells with chimeric ant igen receptors have potent 
antitumor effects and can establish memory in patients with adv anced leukemia. Science 
Translational Medicine. 2011;3(95).
4. Kochenderfer JN, Dudley ME, Feldm an SA, et al. B-cell depletion and remissions of 
malignancy along with cytokine-a ssociated toxicity in a clinica l trial of anti-CD19 
chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
5. Carpenter RO, Evbuomwan MO, Pi[INVESTIGATOR_505614] S, et al. B-cell maturati on antigen is a 
promising target for adoptive T-cell therapy of multiple myelom a. Clinical Cancer 
Research. 2013;19(8):2048-2060.
6. Gattinoni L, Finkelstein SE, Kle banoff CA, et al. Removal of hom eostatic cytokine sinks 
by [CONTACT_330435]-specific CD8+ 
T cells. Journal of Experimental Medicine. Oct 3 2005;202(7):907-912.
7. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Ad optive transfer of 
syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymp homa and normal B cells. Blood. 2010;116(19):3875-3886.
8. North RJ. Cyclophosphamide-fac ilitated adoptive immunotherapy o f an established 
tumor depends on elimina tion of tumor-induced suppressor T cell s. Journal of 
Experimental Medicine. 1982;155(4):1063-1074.
9. Palumbo A, Anderson K. Multiple myeloma. New England Journal of Medicine. 
2011;364(11):1046-1060.
10. Munshi NC, Anderson KC. Plasma Ce ll Neoplasms. In: DeVita VT, L awrence TS, 
Rosenberg SA, eds. Cancer:  Principles and Practice of Oncology 9th ed 2011.
11. Messina C, Locatelli F, Lanino E , et al. Extracorporeal photoch emotherapy for paediatric 
patients with graft-versus-host  disease after haematopoietic st em cell transplantation. Br J 
Haematol. Jul 2003;122(1):118-127.
12. Rajkumar SV. Treatment of multiple myeloma. Nature Reviews Clinical Oncology. 
2011;8(8):479-491.
13. Cherr
y BM, Korde N, Kwok M, Roschewski M, Landgren O. Evolving therapeutic 
paradigms for multiple myeloma: Back to the future. Leukemia and Lymphoma. 
2013;54(3):451-463.
14. Gonsalves WI, Gertz MA, Lacy MQ,  et al. Second auto-SCT for tre atment of relapsed 
multiple myeloma. Bone Marrow Transplantation. 2013;48(4):568-573.
75
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
15. Durie BGM, Harousseau JL, Miguel JS, et al. International unifo rm response criteria for 
multiple myeloma. Leukemia. 2006;20(9):1467-1473.
16. Jakubowiak A. Management Strategies  for Relapsed/Refractory Mul tiple Myeloma: 
Current Clinical Perspectives. Seminars in Hematology. 2012;49(SUPPL. 1):S16-S32.
17. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple 
myeloma relapsing after therapy with IMiDs and bortezomib: A mu lticenter international 
myeloma working group study. Leukemia. 2012;26(1):149-157.
18. Stadtmauer EA, Weber DM, Niesviz ky R, et al. Lenalidomide in co mbination with 
dexamethasone at first relapse in comparison with its use as la ter salvage therapy in 
relapsed or refractory multiple myeloma. European Journal of Haematology. 
2009;82(6):426-432.
19. Bensinger WI. The current status  of reduced-intensity allogenei c hematopoietic stem cell 
transplantation for  multiple myeloma. [Review] [48 refs]. Leukemia. 2006;20(10):1683-
1689.
20. Zeiser R, Finke J. Allogeneic haem atopoietic cell transplantati on for multiple myeloma: 
reducing transplant-related mortality while harnessing the graf t-versus-myeloma effect. 
[Review] [70 refs]. European Journal of Cancer. 2006;42(11):1601-1611.
21. Bruno B, Rotta M, Patriarca F, e t al. A comparison of allograft ing with autografting for 
newly diagnosed myeloma. New England Journal of Medicine. 2007;356(11):1110-1120.
22. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Current Opi[INVESTIGATOR_145098]. 2010;22(2):251-257.
23. Park TS, Rosenberg SA, Morgan RA . Treating cancer with genetica lly engineered T 
cells. Trends in Biotechnology. 2011;29(11):550-557.
24. Morgan RA, Dudley ME, Wunderlic h JR, et al. Cancer regression i n patients after 
transfer of genetically engineered lymphocytes.[see comment]. Science. Oct 6 
2006;314(5796):126-129.
25. Rosenberg SA. Cell transfer imm unotherapy for metastatic solid cancer-what clinicians 
need to know. Nature Reviews Clinical Oncology. 2011;8(10):577-585.
26. Restifo NP, Dudley ME, Rosenbe rg SA. Adoptive immunotherapy for  cancer: 
Harnessing the T cell response. Nature Reviews Immunology. 2012;12(4):269-281.
27. Kershaw MH, Teng MWL, Smyth MJ, Darcy PK. Supernatural T cells:  Genetic 
modification of T cells for cancer therapy. Nature Reviews Immunology. 2005;5(12):928-940.
28. Hoyos V, Savoldo B, Dotti G. G enetic modification of human T ly mphocytes for the 
tr 
eatment of hematologic malignancies. Haematologica. 2012;97(11):1622-1631.
29. Turtle CJ, Hudecek M, Jensen MC, R iddell SR. Engineered T cells for anti-cancer 
therapy. Current Opi[INVESTIGATOR_90307]. 2012;24(5):633-639.
76
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
30. Brentjens RJ, Rivi√®re I, Park JH , et al. Safety and persistence  of adoptively transferred 
autologous CD19-targeted T cells in patients with relapsed or ch emotherapy refractory B-
cell leukemias. Blood. 2011;118(18):4817-4828.
31. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with 
metastatic synovial cell sarcom a and melanoma using genetically  engineered
lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology. 2011;29(7):917-
924.
32. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient  treated with autologous T c ells genetically 
engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
33. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and 
persistence of chimeric antigen receptor-modified T cells in ly mphoma patients. Journal 
of Clinical Investigation. 2011;121(5):1822-1826.
34. Scholler J, Brady TL, Binder-Sc holl G, et al. Decade-long safety and function of 
retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine. 
2012;4(132).
35. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integr ation deregulates gene 
expression but has no consequen ce on the biology and function o f transplanted T cells. 
Proceedings of the National Academy of Sciences of the [LOCATION_002] of America. 2006;103(5):1457-1462.
36. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV- specific T-cell 
infusions to prevent or treat EBV -related lymphoproliferative d isease in transplant 
recipi[INVESTIGATOR_840]. Blood. 2010;115(5):925-935.
37. Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric anti gen receptor with 
modified signaling domains leads to enhanced survival of transd uced T lymphocytes and 
antitumor activity. Journal of Immunology. 2009;183(9):5563-5574.
38. Irving BA, Weiss A. The cytoplasmic domain of the T cell recept or zeta chain is 
sufficient to couple to receptor-associated signal transduction pathways. Cell. Mar 8 
1991;64(5):891-901.
39. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation an d targeting of cytotoxic 
lymphocytes through chimeric sing le chains consisting of antibo dy-binding domains and 
the gamma or zeta subunits of the  immunoglobulin and T-cell rec eptors. Proceedings of 
the National Academy of Sciences of the [LOCATION_002] of America. Jan 15 
1993;90(2):720-724.
40. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long -term fate of chimeric 
antig
en receptor-positive T cells  in patients with neuroblastom a. Blood. 
2011;118(23):6050-6056.
41. Curran KJ, Pegram HJ, Brentjens R J. Chimeric antigen receptors for T cell 
immunotherapy: Current understa nding and future directions. Journal of Gene Medicine. 
2012;14(6):405-415.
77
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
42. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells eng ineered to coexpress 
tumor-specific receptors: persistence and antitumor activity in  individuals with 
neuroblastoma.[see comment]. Nature Medicine. Nov 2008;14(11):1264-1270.
43. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer ce lls by [CONTACT_505671] a c himeric gene composed of an anti body variable region 
and the Fc receptor gamma chain. Journal of Experimental Medicine. Jul 1 
1993;178(1):361-366.
44. Hwu P, Yang JC, Cowherd R, et al . In vivo antitumor activity of  T cells redirected with 
chimeric antibody/T-cell receptor genes. Cancer Research. Aug 1 1995;55(15):3369-
3373.
45. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive 
immunotherapy using gene-modified T  cells for ovarian cancer. Clinical Cancer 
Research. Oct 15 2006;12(20 Pt 1):6106-6115.
46. Kochenderfer JN, Feldman SA , Zhao Y, et al. Construction and pr eclinical evaluation of
an anti-CD19 chimeric antigen receptor. Journal of Immunotherapy. 2009;32(7):689-702.
47. Cheadle EJ, Gilham DE, Thistleth waite FC, Radford JA, Hawkins R E. Killing of non-
Hodgkin lymphoma cells by [CONTACT_419617]19 engineered T cells. British Journal of 
Haematology. May
May 2005;129(3):322-332.
48. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of syst emic B-cell tumors by 
[CONTACT_330436] T lymphocytes co-stimulated by [CONTACT_398]80 and interleukin-
15.[see comment]. Nature Medicine. Mar 2003;9(3):279-286.
49. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling 
capacity provoke potent cytotoxicity against acute lymphoblasti c leukemia. Leukemia. 
Apr 2004;18(4):676-684.
50. Milone MC, Fish JD, Carpenito C , et al. Chimeric receptors cont aining CD137 signal 
transduction domains mediate enha nced survival of T cells and increased antileukemic 
efficacy in vivo. Molecular Therapy: the Journal of  the American Society of Gene 
Therapy. Aug 2009;17(8):1453-1464.
51. Porter DL, BL; Kalos, M et al. Chimeric Antigen Receptor-Modifi ed T Cells in Chronic 
Lymphoid Leukemia. The New England Journal of Medicine. 2011;365(8):725-733.
52. Wang X, Naranjo A, Brown CE, e t al. Phenotypic and functional a ttributes of lentivirus-
modified CD19-specific H uman CD8 + central memory T cells manufa ctured at clinical 
scale. Journal of Immunotherapy. 2012;35(9):689-701.
53. Cooper LJ, Topp MS, Serrano LM, e t al. T-cell clones can be rendered specific for 
CD19: toward the selective augmen tation of the graft-versus-B-l ineage leukemia effect. 
Blood. F
eb 15 2003;101(4):1637-1644.
54. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cel ls to augment disease 
control in patients undergoing a utologous hemato poietic stem-ce ll transplantation for 
advanced B-lymphoid malignancies. Human Gene Therapy. 2012;23(5):444-450.
78
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
55. Hollyman D, Stefanski J, Przyby [CONTACT_398410] M, et al. Manufacturing v alidation of biologically 
functional T cells targeted to CD19 antigen for autologous adop tive cell therapy. Journal 
of Immunotherapy. 2009;32(2):169-180.
56. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor l ocalization, and antitumor 
activity of CAR-engineered T cells is enhanced by [CONTACT_505672]137 (4-1BB). Cancer Research. 2011;71(13):4617-4627.
57. Maher J, Brentjens RJ, Gunset G, Rivi√®re I, Sadelain M. Human T-lymphocyte 
F\WRWR[LFLW\DQGSUROLIHUDWLRQGLU HFWHGE\DVLQJOHFKLPHULF7& 5»ó&'UHFHSWRUNature 
Biotechnology. 2002;20(1):70-75.
58. Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric imm une receptors: Evaluation of four  different scFvs and 
antigens. Journal of Immunotherapy. 2005;28(3):203-211.
59. Rossig C, Bar A, Pscherer S, et al. Target antigen expression o n a professional antigen-
presenting cell induces superior proliferative antitumor T-cell  responses via chimeric T-
cell receptors. Journal of Immunotherapy. Jan-Feb 2006;29(1):21-31.
60. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen imp acts the long-term engraftmen t but not antitumor 
activity of CD19-specific engineered T cells. Journal of Immunology. 2010;184(4):1885-
1896.
61. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic 
acute lymphoblastic leukemia xenografts. Clinical Cancer Research. Sep 15 2007;13(18 
Pt 1):5426-5435.
62. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation prov ided through a 
CD19-specific chimeric antigen r eceptor enhances in vivo persis tence and antitumor 
efficacy of adoptively transferred T cells. Cancer Research. Nov 15 2006;66(22):[ZIP_CODE]-
[ZIP_CODE].
63. Porter CD, Collins MK, Tailor CS, et al. Compa rison of efficien cy of infection of human 
gene therapy target cells via f our different retroviral recepto rs. Human Gene Therapy. 
May 20 1996;7(8):913-919.
64. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene reject ion responses contribute 
to attenuated persisten ce of adoptively transferred CD20/CD19-s pecific chimeric antigen 
receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation. 
2010;16(9):1245-1256.
65. Laabi Y, Gras MP, Carbonnel F , et al. A new gene, BCM, on chrom osome 16 is fused to 
the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a  malignant T cell 
l
ymphoma. EMBO Journal. 1992;11(11):3897-3904.
66. Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A. The  BCMA gene, 
preferentially expressed during B lymphoid maturation, is bidir ectionally transcribed. 
Nucleic Acids Research. 1994;22(7):1147-1154.
79
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
67. Novak AJ, Darce JR, Arendt BK, e t al. Expression of BCMA, TACI,  and BAFF-R in 
multiple myeloma: A mechanism for growth and survival. Blood. 2004;103(2):689-694.
68. Neri P, Kumar S, Fulciniti MT, e t al. Neutralizing B-cell-activ ating factor antibody 
improves survival and inhibits oste oclastogenesis in a severe c ombined immunodeficient 
human multiple myeloma model. Clinical Cancer Research. 2007;13(19):5903-5909.
69. Bellucci R, Alyea EP, Chiaretti S , et al. Graft-versus-tumor re sponse in patients with 
multiple myeloma is associated with antibody response to BCMA, a plasma-cell 
membrane receptor. Blood. 2005;105(10):3945-3950.
70. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect  myeloma cells from 
apoptosis induced by [CONTACT_505673] n 6 deprivation and dexamethasone . Blood. 
2004;103(8):3148-3157.
71. Thompson JS, Schneider P, Kalle d SL, et al. BAFF binds to the t umor necrosis factor 
receptor-like molecule B cell maturation antigen and is importa nt for maintaining the 
peripheral B cell population. Journal of Experimental Medicine. 2000;192(1):129-135.
72. Mackay F, Schneider P, Rennert P , Browning J. BAFF and APRIL: A  tutorial on B cell 
survival .Vol 21. Annual Review of Immunology2003:231-264.
73. Kalled SL. The role of BAFF i n immune function and implications for autoimmunity. 
Immunological Reviews. 2005;204:43-54.
74. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and 
growth of human multiple myeloma  cells in the bone marrow micro environment. Cancer 
Research. 2006;66(13):6675-6682.
75. O'Connor BP, Raman VS, Erickson LD, et al. BCMA Is Essential fo r the Survival of 
Long-lived Bone Marrow Plasma Cells. Journal of Experimental Medicine. 
2004;199(1):91-97.
76. Ng LG, Sutherland APR, Newton R, e t al. B cell-activating facto r belonging to the TNF 
family (BAFF)-R is the principal BAFF receptor facilitating BAF F costimulation of 
circulating T and B cells. Journal of Immunology. 2004;173(2):807-817.
77. Xu S, Lam KP. B-cell maturation pr otein, which binds the tumor necrosis factor family 
members BAFF and APRIL, is dispen sable for humoral immune respo nses. Molecular 
and Cellular Biology. 2001;21(12):4067-4074.
78. Schiemann B, Gommerman JL, Vora K, et al. An esse ntial role for  BAFF in the normal 
development of B cells through a BCMA-independent pathway. Science. 
2001;293(5537):2111-2114.
79. B randtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. 
Immunological Investigations. 2010;39(4-5):303-355.
80. Soutar CA. Distribution of plas ma cells and other cells contain ing immunoglobulin in the 
respi[INVESTIGATOR_505615] n and class of immunoglobulin con tained therein. Thorax. 
1976;31(2):158-166.
80
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
81. Kalled SL, Hsu Y. Anti-BCMA Antibodies. World Intellectual Property Organization 
Patent. Filing date 10 March 2010;Interna tional Publicaton Number WO 20 10/104949 
A2(Patent Applicant Biogen  Idec, Cambridge MA, [LOCATION_003]).
82. Rubio V, Stuge TB, Singh N, et al . Ex vivo identification, isolation and analysis of 
tumor-cytolytic T cells. Nature Medicine. 2003;9(11):1377-1382.
83. Muranski P, Boni A, Wrzesinski C , et al. Increased intensity ly mphodepletion and 
adoptive immunotherapy - How far can we go? Nature Clinical Practice Oncology. 
2006;3(12):668-681.
84. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and 
antigen presenters: How lymphodepletion enhances T cell-mediate d tumor 
immunotherapy. Trends in Immunology. 2005;26(2):111-117.
85. Dumitru CA, Moses K, Trellakis S,  Lang S, Brandau S. Neutrophil s and granulocytic 
myeloid-derived suppressor cells: Immunophenotypi[INVESTIGATOR_007], cell biolo gy and clinical 
relevance in human oncology. Cancer Immunology, Immunotherapy. 2012;61(8):1155-
1167.
86. Lee JC, Hayman E, Pegram HJ, et al. In vivo inhibition of human  CD19-targeted effector 
T cells by [CONTACT_202392] T regulatory cells in a xenotransplant murine model of B cell 
malignancy. Cancer Research. 2011;71(8):2871-2881.
87. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in 
patients after clonal repopula tion with antitumor lymphocytes. Science. Oct 25 
2002;298(5594):850-854.
88. Dudley ME, Yang JC, Sherry R, e t al. Adoptive cell therapy for patients with metastatic 
melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. 
Journal of Clinical Oncology. Nov 10 2008;26(32):5233-5239.
89. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the flud arabine and 
cyclophosphamide combination regimen in chronic lymphocytic leu kemia. Journal of 
Clinical Oncology. 2001;19(5):1414-1420.
90. Klebanoff CA, Gattinoni L, Palme r DC, et al. Determinants of su ccessful CD8 + T-cell 
adoptive immunotherapy for large  established tumors in mice. Clinical Cancer Research. 
2011;17(16):5343-5352.
91. Overwijk WW, Theoret MR, Finkels tein SE, et al. Tumor regressio n and autoimmunity 
after reversal of a functionally tolerant state of self-reactiv e CD8+ T cells. Journal of 
Experimental Medicine. 2003;198(4):569-580.
92. Li S, Yang J, Urban FA, et al. Genetically engineered T cells e xpressing a HER2-specific 
chimeric receptor mediate antigen-spe cific tumor regression. Cancer Gene Therapy. 
2008;15(6):382-392.
93. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological 
malignancies after stem cell transplantation revisited. Cancer Treatment Reviews. 
2010;36(7):528-538.
81
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
94. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: The long and  winding road: how 
should it be traveled? Bone Marrow Transplantation. 2008;42(9):569-579.
95. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cell s rapi[INVESTIGATOR_505616]-refractory acute lymphob lastic leukemia. Science 
Translational Medicine. 2013;5(177).
96. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T ce lls expressing anti-
CD19 chimeric antigen receptors. Nature Reviews Clinical Oncology. 2013;10(5):267-
276.
 
82
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
 
13APPENDICES
13.1 APPENDIX A-P ERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale*
Grade Descriptions
0Normal activity.  Fully active , able to carry on all pre-diseas e 
performance without restriction.
1Symptoms, but ambulatory.  Restricted in physically strenuous a ctivity, 
but ambulatory and able to car ry out work of a light or sedenta ry nature 
(e.g., light housework, office work).
2In bed <50% of the time.  Ambulat ory and capable of all self-ca re, but 
unable to carry out any work activities.  Up and about more tha n 50% 
of waking hours.
3In bed >50% of the time.  Cap able of only limited self-care, co nfined to 
bed or chair more tha n 50% of waking hours.
4100% bedridden.  Completely disa bled.  Cannot carry on any self -care.  
Totally confined to bed or chair.
5 Dead.
* As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H. , Tormey, D.C., Horton, J., 
Davis, T.E., McFadden, E.T., Car bone, P.P.: Toxicity And Respon s e  C r i t e r i a  O f  T h e  E a s t e r n  
Cooperative Oncology Gr oup. Am J Clin Oncol 5:649-655, 1982.
83
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
13.2 APPENDIX B: D ATA COLLECTION ELEMENTS REQUIRED BY[CONTACT_505674] i n the C3D datab ase:
A. Patient Enrollment
xDate of birth, age, gender, race, ethnicity
xHeight
xWeight
xPerformance Status
xDate of original diagnosis
xStage at diagnosis
xPlasmacytoma present: Yes or No
xTumor Histology and date of confirmation
xBCMA expression by [CONTACT_505675], consent version and date of  registration
xBaseline History/Physical
xBaseline Symptoms 
xPrior therapy
xPrior radiation
xPrior Bone Marrow Biopsy that inc ludes the percent of plasma ce lls and the percent 
of BCMA cells
xFindings of consultations done at screening
B. Study Drug administration and re sponse for eac h course of the rapy given
xDates anti-BCMA-CAR-transduced T cells given
xDose level, actual dose, s chedule and route given
xHeight, weight, and body surface  area at start of each course
xResponse assessment for each restaging performed
xConcomitant medications will not be collected in C3D
C. Laboratory and Diagnostic Test Data
1. All Clinical laboratory and diagnostic test results done at s creening and until day 
[ADDRESS_652384] infusion with the following exceptions:
Diagnostic tests which are not specified in the protocol, and i f the results are not 
needed to document the start or  end of an adverse event that re quires reporting.
Serologies-CMV, HSV, EBV, toxoplas mosis, adenovirus (patient and donor)
TTV data 
2. All staging studies including  serum protein electrophoresis, urine protein 
electrophoresis, serum free light chains, bone marrow biopsy reports, flow cytometry reports, serum immunoglobulin reports including beta-2  microglobulin,
84
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
complete blood count and differential reports, serum creatinine  reports, TBNK 
results, serum protein, urine albumin, serum calcium (including i onized), ESR and 
CRP results. MRI, X-ray (including skeletal survey), and CT scan  r e s u l t s  w i l l  
only be reported if they were used for staging.
D. Adverse Events
Please see section 6.1.1 Adverse Event Recording
E. Tumor response and measurements
xRestaging studies performed at protocol specified time points a nd as clinically 
indicated.
xAny physical exam findings will be  collected as Adverse Events an d labs results.
xYears 5-15 follow-up is only for survival.
F. Off study
xDate and reason for off study
xDate and cause of death
xAutopsy findings
xPI [INVESTIGATOR_505589]
85
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
13.3 APPENDIX C: G UIDELINES FOR MANAGEMENT OF COMMON TOXICITIES THAT OCCUR 
AFTER CAR T- CELL INFUSIONS
Infusions of CAR T cells are often complicated by [CONTACT_505676] [ADDRESS_652385] different toxicities.
Suggested Guidelines for comm on acute CAR T-cell toxicities
Note these are guidelines that mig ht require modification based  on clinical circumstances of each 
patient, and failure to e xactly follow these guidelines is not a protocol deviation.
Administration of cor ticosteroids should be  avoided if at all p ossible to avoid killing or 
impairing the function of the CAR T cells.
1. All patients with significant  malignancy burdens and without a contradiction such as allergy 
should be started on allopurinol at the time of the start of the  chemotherapy conditioning 
regimen or 1 day before the CAR T cell infusion. The suggested a llopurinol dose is 200 to 
300 mg/day with a possible loading dose of [ADDRESS_652386] ins and outs should  be recorded on all patients.
4. Fevers should be treated with acetaminophen and comfort measu res. NSAIDs and 
corticosteroids should be avoided.
5. Administer fresh frozen plasma (FFP) for a PTT 1.5-fold or mo re above the upper limit of 
normal.
6. For patients with an increased PTT, check the fibrinogen leve l and keep the fibrinogen level 
above 100 mg/dL with cryoprecipi[INVESTIGATOR_047].
7. Patients with a heart rate persistently higher than 115/minute  and fever should have vital 
signs checked every [ADDRESS_652387] fall precaut ions including instructions to get out 
of bed only with assistance under the following conditions:
86
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652388] orthosta tic blood pressure 
and heart rate checked and receive intravenous fluids as approp riate. These patients will also 
receive an ECG.
Hypotension is a common toxicity requiring intensive care unit (ICU) admission.  In general 
patients should be kept well-hydr ated.  Maintenan ce I.V. fluids (normal saline (NS) should be 
started on most patients with hig h fevers especially if oral in take is poor or the patient has 
tachycardia.  I.V. fluids are not necessary for patients with g ood oral intake and mild fevers.  
For patients who are not having hypotension or tumor lysis synd rome, a generally even fluid 
balance should be strived for aft er allowing for insensible flu id losses in patients with high
fevers.  The baseline systolic b lood pressure is defined for th is protocol as the average of all 
systolic blood pressure readings obtained during the [ADDRESS_652389] treatment for hypoten sion is administration of IV NS boluses.  
xPatients with a systolic blood pr essure that is 80% or less of their baseline blood 
pressure and less than [ADDRESS_652390] a stat EKG and troponin, and a 
cardiac echocardiogram within 24 hours.
11. Patients should be transferred to the ICU under these circums tances.  Patients not meeting 
these criteria could also require ICU admission at the discretio n of the clinical team caring 
for the patient.
xSystolic blood pressure 75% or le ss than the patient‚Äôs baseline blood pressure and 
less than [ADDRESS_652391] nasal cannula
xGreater than grade 2 neurological toxicity
87
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652392] a cardiac  echocardiogram and an EKG withi n 24 hours of starting 
norepi[INVESTIGATOR_238].
15. Patients in the ICU should get twice-daily labs (CBC with di fferential, acute care panel, 
mineral panel, hepatic panel, ur ic acid, LDH.  Patients in the ICU should also get a daily 
troponin level). 
16. Anecdotal evidence suggests that the IL-6 receptor blocker t ocilizumab can be an effective 
treatment for cytokine-release sy ndrome toxicities after CAR T- cell infusions. Tocilizumab 
should be administered under the fo llowing circumstances if the  listed disorders are thought 
to be due to cytokine release fro m CAR T cells.  Tocilizumab is  administered at a dose 8 
mg/kg infused IV over 1 hour  (dose should not exceed 800 mg).
xLeft ventricular ejection fraction 40% or less by [CONTACT_505677] 2.5-fold higher than the most recent le vel prior to CAR T-
cell infusion
xNorepi[INVESTIGATOR_505617] 3 Pg/min or more for [ADDRESS_652393] 
administration of norepi[INVESTIGATOR_505618].
xSystolic blood pressure of 90 mm Hg cannot be maintained with norepi[INVESTIGATOR_238].
xOxygen requirement 55% or greater fraction of inspi[INVESTIGATOR_1401] (F IO2) for more 
than 2 continuous hours.
xDyspnea that is severe enough to potentially require mechanical  ventilation.
xPTT or INR>2x upper limit of normal
xClinically-significant bleeding
xCreatine kinase greater tha n 5x upper limit of normal for great er than 2 days
17. THERE IS NO EVIDENCE THAT TOCILIZUMAB HELPS NEUROLOGICAL 
TOXICITY, SO IT SHOULD NOT BE ADMINISTERED FOR THIS PURPOSE.
18. If no improvement in hypotension or tachycardia occurs within  6 hours of tocilizumab 
infusion, consider other agents such as methylprednisolone 1 mg/ kg every 12 hours or 
etanercept.
19. Avoid meperidine due to seizure risk.
20. In the setting of cytokine-release syndrome, patients with a  left ventricular ejection fraction 
of 30% or less and patients who in the opi[INVESTIGATOR_505619] 
88
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
needing intubation in the next 4 hours should be given methylprednisolone 100 mg every 6 
hours.
21. Some patients may experience decreases in serum immunoglobul ins.  Replacement of 
serum IgG with intravenous IgG is recommended for serum IgG lev els below 400 mg/dL.  
22. In general, follow standard vaccination practices including an annual influenza vaccination 
in the absence of data t o suggest otherwise.
23. All patients with grade [ADDRESS_652394] been given.
1. Patients with Gra de 3 or 4 neurological toxicities except that  
dexamethasone is not reco mmended for iso lated Grade 3.
2. Any generalized seizure
89
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
13.4 APPENDIX D: I NFUSION INSTRUCTIONS   
Equipment:  
Primary IV tubing (2)Secondary IV tubing (1)NS (sodium chloride 0.9%) 250cc bags (2)IV infusion pumpGloves
Steps: Key Points:
1.  On the morning of infusion the primary 
RN will be notified of the approximate time TIL cells will be ready (usually between 11AM and noon).
2.  Verify the physician orders:
- to administer the cells- for the date of a dministration
- for premedication orders - protocol numberxPremeds are acetaminophen 650 mg 
PO and diphenhydramine 12.5 mg 
IV.
3.  Verify that the protocol consent and DPA are signed.
4.  Ensure that emergency and monitoringequipment are available in the patient‚Äôs room:
- oxygen- suction- vital sign monitor with pulse oximeter
and thermometer   
90
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652395] baseline vital signs, respi[INVESTIGATOR_419523].
8.  Verify the patency of the patient‚Äôs IV access.A central venous access device such as a non-valved PI[INVESTIGATOR_419524].
9.  Hang a primary line of 250cc NS at a kvo rate - NEW bag and NEW tubing. 
This MUST be ready and infusing prior to 
the cells being delivered to the unit.
The patient‚Äôs primary IV hydration can 
infuse via a separate lumen while the cells are infusing, but NO MEDs should be
administered during this time.
Have a second bag of 250cc NS and tubing 
ready as an emergency line.This will be the dedicated NS line for infusing the cells.  Under no circumstances are any other substances to be infused into the line.  
Cell death occurs quickly ‚Äì the infusion 
must be initiated immediately. 
Do not infuse medication during the cell 
infusion.  If emergency meds must be administered, use the hydration or emergency NS IV line. 
This will be the emergency IV solution 
and can be used for medicationadministration.
Do not use an inline filter for cells.
10.  The primary RN will be notified 
approximately 10 minutes before the cells arrive on the unit.  The cells will be hand delivered to the bedside.
It is critical to be at the bedside awaiting 
the arrival of the cells for infusion.  It is critical to be at the bedside awaiting the arrival of the cells for infusion; have baseline VS, assessment, and IV lines hooked up when the cells arrive.  Cell 
death occurs as soon as the cells are removed from the laboratory .  Initiate the 
infusion as quickly as possible .
12.  Prior to spi[INVESTIGATOR_419525], two RNs will perform the identification procedure.  
91
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, [ADDRESS_652396] sign the tag on the cell bag.
13.   Infuse the cells by [CONTACT_505678] 
20  minutes.
a .  P i g g y b a c k  t h e  c e l l s  i n t o  t h e  dedicated NS line; use the backflush technique to prime the line.
b. While the cells are infusing, gently
a g i t a t e  t h e  b a g  o f  c e l l s  every few 
minutes to prevent clumpi[INVESTIGATOR_419527]. When the cell bag is empty, 
backflush NS to rinse the bag and infuse this at the same rate as the cells; rinse bag until NS runs clear.
Note, when very small cell doses are 
given, the cells will arrive at the bedside in a syringe.  In these cases, the cells should be manually infusedover [ADDRESS_652397] VS before and after the cell infusion, q1h x 4and then q4h after completion of the infusion.  
a.  Assess and document the    patient‚Äôs respi[INVESTIGATOR_505620].
15.  Documentation:
a.  After the cells have infused, remove the adhesive backed ‚Äúcell therapy product‚Äù tag from the cell bag and place it on a progress note in the patient‚Äôs chart. 
b.  Document the cell infusion in  
CRIS using the appropriate screens.  